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SYNOPSIS 
A study of the luminescence properties of alpha-1-acid glyco-
protein (cx1AAGP) and its basic drug binding properties was carried out. 
The fluorescence and phosphorescence properties of the protein were 
studied. The luminescence were found not to differ from those of a typical 
protein. 
The effect of basic drug binding on the cx1 AAGP fluorescence or 
the drug fluorescence quantum yield was investigated. Drugs studied were; 
propranolol, chlorpromazine and imipramine. Only chlorpromazine showed 
quenching of the protein fluorescence. 
DAPN,l- U 2- (5- dimethylamino)naphthalene- 1 - sulphonylamino-
ethyl] -amino)- 3 - (1 - naphthaleneoxy)- 2- propanol, was used as a basic 
fluorescent probe for cx1 AAGP. DAPN fluoresces only slightly in aqueous 
solution (Aexc. 330nm, Aem. 555nm). On binding to cx1AAGP, there is a 
30nm blue shift in the emission maximum and the emission intensity 
increased about 10 times at pH 7.4. A stable complex was formed, 
association constant about 3 x 106M-I at one strong binding site. Other 
weaker binding sites were discernible. 
DAPN competed with basic drugs for the same binding site, the 
most effective competitors being the tertiary and secondary amine 
derivatives. Displacement of DAPN from the cx1 AAGP binding site by a 
• 
basic drug produced fluorescence quenching which was used for binding 
measurements. The binding constants of some basic drugs (amitriptyline, 
propranolol, chlorpromazine, imipramine and erythromycin) were 
evaluated. TBEP, a plasticiser, also gave a strong displacement effect on 
DAPN but steroids did not affect the DAPN binding to cx1AAGP, neither 
did the immunoreaction of cx1AAGP affect the DAPN binding. 
(iii) 
The binding of DAPN to human serum was studied. Besides 
oc1AAGP only albumin and p-!ipoproteins showed affinity for DAPN. 
Further studies were carried out to determine the nature of the 
binding sites. The binding of DAPN to oc1AAGP was not affected by the 
removal of sialic acid from the protein. Urea denaturation removed the 
binding totally. Dissociation of the disulphide bridges of the oc1AAGP also 
destroyed the binding site completely. Maximum binding occurred between 
pH 7 and 10. 
The binding of DAPN to oc1 AAGP, and the basic drug binding 
displacement methods have been automated successfully by flow injection 
analysis. A gradient f.i.a technique was also applied. Binding parameters 
determined by the f.i.a methods compared very well with those determined 
by the static methods. 
• 
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Chapter 1 
INTRODUCTION 
1.1 Drug-Protein Binding Interactions 
Drug-protein binding (DPB) is essentially an interaction between a 
biological macromolecule, the protein, and a small drug molecule. The 
interaction is analogous to enzyme substrate binding, except that the 
complex formed does not dissociate to yield a product. The complex is 
formed by non-covalent or, rarely, by covalent chemical reactions with 
active chemical groups in the protein molecule. The association is termed 
binding in either case and the associated drug is termed 'bound', while the 
unassociated drug is termed 'free'. Similar analogies are used for the 
protein that is bound or not involved in the association respectively. 
1.1.1 Non-covalent Binding Interactions 
Reversible interactions between a small molecule and a protein 
involve several bonds of different types. In non-covalent reactions, bonds 
similar to those between the small molecule and the protein are also 
formed between the drug and the surrounding solvent. Hence, at any time, 
the drug is distributed between the protein and the solvent. A certain 
. fraction is bound to the protein. The distribution is therefore dynamic and 
competitive between the solvent and the protein molecule. Ionised or non-
ionised groups of the drug and the protein may be involved. Any factor 
which modifies the nature of the binding system, for example pH or 
temperature or presence of other molecules, such as detergents or lipids, 
can cause changes in the degree of binding. Thus: 
2 
B + L K' ___b BL (1) 
~ 
where B represents the unbound protein sites, L the free ligand; K~ and K~ 
are the TO..'ce: constants for the forward and reverse reactions 
respectively. At equilibrium the ratio of the forward reaction constant to 
the reverse reaction constant is known as the association constant or 
binding affinity constant, Ka (litre mole -l) as defined in the following 
equation; 
= 
[BL) 
[L)[B] 
or 
[ 1 or C stand for concentration 
(2) 
The inverse of the constant, Ka is known as the dissociation constant, Kd 
(mole litre - 1) 
The binding of drugs to proteins often involves more than one 
binding site on the protein molecule and the quantitative description 
generally assumes that all sites on the protein are independent and 
identical. For such a binding system the following equations define the 
equilibrium between a ligand and the sites on the protein: 
p + nL (3) 
where n is the number of binding sites and P is the protein. Alternatively, 
a step wise addition of ligand may occur as: 
p + L Kl PL1 (4) 
PL1 + L 
K2 
PL2 (5) 
PLn-1 + L 
Kn 
PLn (6) 
where at equilibrium 
3 
= 
(7) 
[PLi_1 ] [L] 
A full description of ligand-protein binding is given in a number of 
reviews.1- 5 
In reality, the binding sites of the protein are rarely identical and 
cooperative interactions are often encountered. The cooperative effect, 
which is the influence of an occupied binding site on the Ka values for 
other binding sites, may result from any of the following factors: 
1. Steric interference between bound molecules; 
2. When the ligand is charged, electrostatic interactions may arise 
from the increasing charge on the protein as more ions are bound; 
3. Conformational changes of the protein may be induced by 
interaction with the ligand. This may either increase or decrease 
the Ka values of the other binding sites. 
In such cases the binding will not behave in accordance with equation (2). 
Some aspects of non-identical binding sites have been examined 
mathematically by several authors and the practical implications have also 
been discussed. 6• 7 
1.1.2 The Nature of Drug-Protein Interactions 
It is generally assumed that non-covalent binding is predominantly 
a result of hydrophobic interactions. 7 •8 Evidence also supports the 
involvement of ionic forces, hydrogen bonding and Van der Waals forces in 
the binding. 8 Early investigators on the binding of organic ions by proteins 
showed that the association constant increases with the increasing 
molecular mass of the ion.l•4 Although different proteins bind to small 
4 
ions to different degrees, all proteins bind to organic ions to some extent. 
Within a homologous ligand series the binding affinity usually increases 
with the size of the ion.1 
~Y'-' 
Protein-ligand complexes are formedA between milliseconds and 
microseconds - the rates of which have been studied by modern high-speed 
relaxation methods. However, if a change in the conformation of the 
protein is involved binding may take several seconds or even minutes. 2 
1.2 The Significance of Drug-Protein Interactions 
Drug action in the body involves interaction with macromolecules 
including a whole range of receptor sites in neurons, transport systems, 
membranes and enzymes. To exert its effect, a drug must reach its target 
organ in an amount sufficient to evoke a biochemical or physiological 
response and only a 'free' drug is capable of diffusing to the organ site. 
The fraction of drug dose that ultimately reaches its site of action depends 
not only on the dose and the physicochemical properties of the drug but 
also on interactions with non-action sites such as tissue and plasma 
proteins. Such interactions affect the rate at which a drug is absorbed 
from the gastrointestinal tracts, distributed and transported to various 
organs for metabolism and elimination. 
1.2.1 The Effect of Protein Binding on Absorption 
Many drugs are so insoluble in water that they could not be 
transported in the blood were it not for their association with proteins. 
Many drugs remain largely in their ionised forms at all levels in the 
gastrointestinal tract. Additionally, the pH of plasma water is such as to 
5 
discourage bases from penetrating the intestinal wall. The binding of the 
drugs to plasma proteins facilitates the transfer of drug molecules across 
from the intestinal lumen into the blood, When a drug is highly bound to 
plasma proteins, absorption into the blood is also favoured because a larger 
concentration gradient is maintained between free drug at the absorption 
site and that in the plasma. 
1.2.2 The Effect of Protein Binding on Drug Distribution 
Macromolecules and their complexes can pass across membranes 
only with great difficulty and only the free drug can diffuse across 
membranes between the plasma and extravascular fluid. Hence the binding 
of a drug to protein can influence the distribution of the drug within the 
body./ Martin9 showed that the greater the binding to plasma proteins 
the lower the concentration of the free drug distributed at equilibrium 
I 
between the tissue compartment and the plasma water,/ Several models 
show that strongly plasma bound drugs tend to have a low apparent volume 
of distribution (the total amount of drug in the body after the distribution 
phases are completed; divided by the plasma concentration) which is 
arguable from Fig. 1.1. /Martin also showed that for drugs possessing high ·, 
values of Ka (greater than ··104M-1) there exists a dose range within which 
small increases in the dose will produ<!e relatively large and dispropor-
tionate in<!reases in the <!On<!entration of the free drug; presumably be<!ause 
the protein binding sites have become saturated. 
Ordinarily the binding of a drug to plasma proteins slows the rate of 
distribution of the drug into peripheral compartments of the body. 
However, when the rate of clearance of a drug in an organ is higher than 
the rate of blood flow to the organ, binding to plasma proteins may 
Figure 1.1 
PLASMA 
Bound 
drug 
1 ~ 
Free 
drug 
I 
J 
I 
I 
I 
TISSUES 
Bound 
drug 
1l 
Free 
drug 
Distribution of drug between plasma and tissue 
compartments. Only free drug can diffuse out of the plasma. 
Free drug concentrations in the tissue and plasma compart-
ments is always therefore equal. Quantities of drug bound 
will depend on the amount of binding materials present in 
both plasma and tissue and their respective binding 
capacities. 
6 
accelerate the rate of distribution. A more critical and detailed analysis 
of this has been given by Gillette.10 
As in plasma, similar interactions occur with tissue proteins. 
Albumin and ligandin are some of the proteins known to have affinity for 
drugs in tissues.11 Some lipid soluble drugs may become localised at 
7 
relatively high concentrations in the brain;12 drugs with plan~r aromatic 
rings such as chlorpromazine and antimalarial drugs combine ~ith DNA;13 
Chlorpromazine binds to the melanin granules of the eyes and skin.14 On 
the whole both tissue and plasma binding affects the distribution of drugs. 
1.2.3 The Effect of Protein Binding on the Metabolism 
The binding of drugs to plasma proteins may also affect their 
metabolism. This depends on whether or not active processes are involved 
in the metabolic activity of the drug. If a drug is highly cleared during its 
passage through the metabolising organ plasma binding will make more 
drug available for biotransformation by diminishing its diffusion to more 
distant tissues. An example of such a drug is propranolol. IS Some drugs 
will depend more on passive uptake mechanisms and only free drug will be 
available for the metabolism. Hence plasma protein binding may offer a 
protective role for the intact drug,16 
1.2.4 The Effect of Protein Binding on Elimination 
The binding of drugs to proteins lowers the concentration of free 
drug in the blood and thereby decreases the rate of elimination by 
glomerular filtration. Protein binding predisposes a drug towards biliary 
excretion16 and some drugs are passively excreted in saliva in 
concentrations equal to the unbound drug in plasma. The dependence of 
elimination on protein binding is often complex especially coupled with 
metabolism. The diverse effects of binding on drug elimination has been 
worked out by Gillette.10 Tissue binding by lowering both total and free 
concentrations of drugs in plasma, will also lead to a decreased drug 
elimination. 
·I 
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1.2.5 The Clinical Significance of Drug-Protein Binding 
It is generally believed that a drug's action is dependent on its \ 
concentration in plasma water. Most blood level measurements in a 
patient's plasma concerns the total drug present, although in a few settings 
emphasis has been placed recently on the free drug. However, to achieve 
the proper amount of the drug in patients, determination of both the free 
and plasma-bound concentrations are required. In cases whereby only total 
plasma level of the drug is measured decreased binding will increase the 
concentration of the free drug and the intensity of the drug effect may 
become greater than expected and may fall within the toxic range. 
Determination of the extent of binding is particularly important when the 
drugs prescribed are characterised by a narrow therapeutic range, for 
example digoxin, or by a marked interindividual variability in rates of 
metabolism, for example tricyclic antidepressants, or by pharmacokinetic 
effects that are difficult to evaluate.16( The. best in vivo correlation of 
serum protein binding and adverse drug reaction was reported by 
Greenblatt et al.l7 Dayton et al.18 have proposed models for the studies, 
in quantitative terms, of the anticipated order of magnitude of drug 
effects that might be attributed to changes in plasma protein binding. 
1.2.6 Competition Between Drugs for Binding Sites 
I 
r 
The addition of another drug to a primary drug regimen can result --.) 
in drug displacement either at plasma or tissue binding sites or in both · / 
~ ... tt"~ area~fTDisplacement from a protein site will depend on the affinities of 
the interacting drugs for the binding sites and also on the concentrations of 
the competing drugs. The drug with the larger association constant may 
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displace the other drug. However, the binding of both drugs will be 
,......- --
decreased. Many drugs, anionic and cationic, are known to compete within 
·-- -· --- ---- ~~ -. 
their groups for the same binding sites on plasma proteins:fV Parent drugs 
? 
may not themselves take part in the competitive displacement but their 
metabolites may be involved. This is clearly demonstrated in the 
interaction between t_he_ metabolite of chloral hydrate, trichloroacetate,_ I 
.. ---,) 1 '1 
\'lhich gives rise to warfarin displacement}-9-
_Non-competitive binding inhibition can also take place at plasma 
binding sites. One drug, by its binding to the protein, may cat,~se 
~-- .. --
conformational changes of the protein which may change the shape of 
gC ~ 
specific binding sites of other drugs;2o J Some drugs can be converted in the 
body to potent alkylating and arylating metabolites that can bind covalently 
. . 
w!_tll proteins,_ particularly tissue proteins. Aspirin permanently acetylates 
thelysine residues of albumin and inhibits the binding of certain drugs by a 
_...--....;>1,... 
non-competitive mechanism.'?.!! 
Many non-drug substances in the blood are also avidly bound to 
plasma proteins and inhibit the binding of drugs. For example, fatty acids 
are known to ilffect the binding of phenylbutazone, warfarin and many 
--. '2.., 
other acidic drugs to plasma albumin;22 and bilirubin affects the binding of 
""---·" ~· '' ' -
23' '" certain sulphonamides to serum albumin, --! 
__ In vitro studies have revealed a number of complexities with this 
kind of drug interaction. ___ Sites that avidly bind one drug may be different 
from those that bind another. For this reason, not all highly bound anionic 
drugs can displace one another from serum protein. For example, 
camptothecin can be displaced from albumin by phenylbutazone but not by 
dicoumarol even though all three drugs are highly bound to albumin.22 A 
drug may be bound to a number of binding sites on the serum protein 
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molecule. Thus, a drug may be displaced from only some of its binding 
sites_ by another drug. Substances that do not share a binding site on ·a 
protein may also displace a drug !rolll_its different binding sites. / 
Competitive and non-competitive inhibitions of drug binding to 
specific tissue binding also occur, although less information is available:_..-
1.2.7 Clinical Significance of Protein Binding 
Displacement Interactions n/. •. 
l '··' 
The unbound forms of most drugs distribute with body water. In a 
70kg man the volume of distribution of the unbound drug would be about 
50 litres.10 In contrast, the volume of distribution of drug-albumin 
complex which is confined only to plasma albumin is about 5.5 litres and 
even less for other protein complexes. It is thus clear that even large 
displacement of a drug from serum protein sites would result in a very 
small increase in free drug concentration after redistribution and 
equilibration. The therapeutic outcome of plasma displacement is 
therefore not significant. However, certain instances do arise whereby the 
phenomenon can lead to an adverse clinical outcome as outlined below: 
1) Rapid intravenous injection of a displacing agent could cause an 
instantaneous increase in the concentration of unbound drug. 
Hence rapidly per fused organs such as the endocrine glands, liver, 
heart and brain, could be exposed to a very high concentration of 
unbound drug which would not normally occur. The best known 
example of this is the intravenous administration of sulphon-
amides to neonates. This results in the displacement of plasma-
bound bilirubin which enters cerebrospinal fluid giving rise to a 
severe case of jaundice. 24 
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2) Displacement of drugs by endogenous substances is important in 
diseased patients where there may be disturbed levels of 
endogenous substances in the blood. The effect of changed levels 
of free fatty acids have recently been described. 25 
3) When the total drug present in plasma is considered, drug 
displacement would result in decreased total drug level which can 
greatly influence the outcome of plasma drug monitoring. Free 
drug concentration after displacement and equilibration would be 
approximately normal due to the increased volume of distribution; 
but unknown to the prescriber, dosage based on the lowered total 
drug level could be increased, followed by therapeutic 
consequences. 
1.2.8 Tissue Binding Displacement 
Displacement from tissue binding sites gives rise to a reversal of 
the effects seen after displacement from plasma binding sites.13 However, 
as the extravascular tissue volume is greater than plasma volume the 
distribution of displaced drug from the tissue into the plasma compartment 
cannot buffer the impact of increased amounts of free drug in the body. 
Tissue binding displacement in isolation is therefore more likely to lead to 
adverse effects than displacement from plasma proteins. An interaction 
giving rise to displacment at both sites could lead to even higher free drug 
concentration in the plasma. 
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1.3 Drug-Protein Binding Determinations 
Drug protein binding interactions are studied in order to: 
1) Determine the affinity of binding; that is, the binding constants 
including cooperative interactions and mechanisms; 
2) Examine saturation and the number of binding sites on the 
protein; 
3) Gain information about the nature of the binding sites; that is, the 
active groups in the protein molecule and molecular conformation 
or dislocation involved in the drug-protein complex; 
4) Identify and define the primary protein components of the plasma 
responsible for the binding interaction and the degree of 
specificity; 
5) Find out possible displacement effects as a result of competition 
between different drugs on the same protein sites. This includes 
displacement effects of endogenous and other molecules 
encountered in the binding studies. 
1.3.1 Plasma Proteins Responsible for Drug Binding 
The primary functions of plasma proteins include the transport of 
substances such as metal ions, fatty acids, steroids, hormones and drugs 
etc. Though diverse in themselves, the plasma proteins are specific in 
their interactions. The transport of small molecules is assigned to the 
members of the plasma group called the ~and {!-globulins, and albumin. 
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For example: 
1) Metal binding globulins, transferrin and ceruloplasmin interact 
with iron and copper respectively; 
2) <X- and '(l-lipoproteins account largely for the binding of lipid 
soluble molecules such as vitamins A and D, (lholesterol and 
,, 
steroid hormones; 
3) Albumin has been assigned numerous roles including transport of 
fatty acids, bilirubin, and many other endogenous substances and 
drugs. 
1.3.2 The Binding of Drugs to Plasma Albumin 
Many studies considered plasma albumin by itself as the binding 
biomolecule, without any attempt to investigate or define other protein 
components responsible for drug binding in plasma~/ Albumin is the most ? 
abundant protein in blood plasma (60% of the total plasma proteins). It 
associates with large numbers of compounds, both charged and neutral/and 
an enormous literature exists on the binding of acidic drugs to human 
serum albumin, as reviewed by Bridges et al. 26a 
1.3.2.1 Survey of albumin-drug binding 
A characteristic feature of albumin-ligand interactions seems to 
be the presence of one or two high affinity binding sites (primary sites) and 
a number of sites with a lower affinity. At high ligand to albumin ratios 
several additional ligand molecules can bind with a low affinity and 
presumably in an unspecific manner. This type of interaction is probably a 
corn m on property of many proteins. The binding affinities and the total I 
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number of binding sites vary with the nature of the ligand.1•26b Among the 
endogenous compounds, bilirubin, long-chain fatty acids are bound with a 
high affinity (Ka approx. I08M-1}. In contrast, steroids and L-thyroxine 
possess association constants one to four orders of magnitude lower. Most 
anionic drugs appear to have one primary binding site that has an affinity 
several fold higher than those of other sites. Both negatively charged and 
electrostatic neutral drugs are bound to albumin with comparable 
association constants (104 to 105M-1}. However, very high values have 
been reported for some drugs, such as iophenoxate and iopanoate 
(approx. 108M-1}. 27 
Attempts have been made by many workers to explore the 
possible number of binding regions necessary to explain the binding 
properties of albumin. It has been suggested that the pronounced capability 
of albumin to associate non-covalently with many ligands is due to the 
existence of at least six binding regions in the protein molecule. 28 This 
finding was based on competitive binding studies. However, many different 
ligands bind competitively at a single primary site of the albumin. The 
ability to bind several ligands with high affinity, based on the existence of 
several binding regions possessing various degrees of specificities, may be 
the property of many plasma proteins. 
Varying substituents on ligand molecules can cause great changes 
in the ligand-protein interaction. For example, iopanoate and iophenoxate, 
which differ by an amino group in the structure of iopanoate and a hydroxy 
group in the case of iophenoxate are bound to different primary binding 
sites of human albumin. 29 Furthermore, ampicillin, in contrast to 
penicillin G ·(they differ by an amino group} is able to displace bilirubin 
from albu)l_min. 30 Ligand binding to protein is in some cases 
.• 0 }Jv-
\ 
\ 
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stereospecific. For example, d-oxazepam is bound to human albumin with 
an affinity thirty to forty times greater than that of the L-isomer. 31 The 
protein binding constants of steroids are not the same when substituents 
are located in the oc- or ~-position. 32 Isomeric compounds can interact 
with human albumin in different ways. For example, when the sttuctmally 
t"elatee dye methyl red interacts with bovine albumin the binding affinity is 
greater for paramethyl red than for the ortho-isomer. The least binding is 
obtained with the meta-isomer which, unlike the other isomers, is 
temperature dependent. The three methyl red isomers do not compete for 
the same primary binding site. 34 The binding constant and specificity of 
drugs to albumin and probably other proteins may hence be critically 
dependent on the presence of a particular chemical group. 
1.3.2.2 The nature of binding sites 
An important aspect of the study of binding sites is an 
identification of amino acid residues lining the binding region. This was 
corn m only achieved by modifying specifically amino acid residues of the 
protein by reactive compounds, after which the ligand binding ability of the 
modified protein molecule is compared to that of the native protein. Many 
workers used this method to study the kinds of amino acids that take part 
in forming the different binding regions of the albumin, including those of /) 
the drugs. 28 
Another method used is the study of the ligand binding to 
fragments of albumin. 28 According to this procedure, a part of the 
albumin is isolated and is able to bind the ligand in question with the same 
or slightly lower affinity as that of the intact albumin. By comparing the 
amino acid sequence of the fragment with that of the intact protein, the 
position of the fragments in the intact albumin can be determined. 
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The interaction between albumin and ligand is often accompanied 
by detectable conformational changes of the protein. Due to the limited 
information on the three-dimensional structure of albumin the exact nature 
of the conformational changes, as recorded by various techniques, is 
difficult to uncover. However, it has been possible to gain insight into 
various aspects of the ligand-protein interaction by conformational studies 
of the protein. Cooperative binding of ligands to albumin is a 
manifestation of ligand-introduced conformational changes. 
1.3. 2.3 Basic drug binding 
Despite the fact that albumin itself carries a net negative charge, 
at physiological pH, it is able to bind anionic and neutral drugs in 
preference to cationic drugs. In fact basic drug binding to· albumin is 
observed only in vitro and not in vivo. As such, protein binding of basic 
drugs escaped attention until recently because most studies assumed that 
albumin is the only plasma protein responsible for drug binding. 
1.3.3 Alpha-1-Acid Glycoprotein and Basic Drug Binding 
Alpha-1-acid glycoprotein (oc1AAGP), otherwise known as 
orosomucoid has recently emerged as the plasma protein;, able to bind basic 
drugs with great affinity. The role of fHipoproteins in the transport of 
basic drugs in plasma has also been reported34 but the binding affinity is 
not large enough to explain the binding of basic drugs to proteins in plasma. 
With regard to affinity, oc1 AAGP appears to dominate in basic drug binding 
to plasma. 
-----------------------------
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1.3.3.1 The properties of <X1-acid glycoprotein 
Alpha-1-acid glycoprotein contains a single polypeptide chain to 
which five heteropolysaecharide groups are linked. The single polypeptide 
possesses an amino terminal, pyroglutamic acid, and a carboxyl terminal, 
serine. Schmid and coworkers35 were successful in elucidating the 
complete amino acid sequence of the protein. The sequence reveals a 
highly hydrophilic molecule with a very high number of dissociable 
residues. This property is attributable to the sialic acid and the hydroxyl 
groups of the sugar residues. There is multiple amino acid substitution 
which is a property shared as far as is known only by· the immune-
globulins. 36 The protein has two disulphide bonds, and molecular weights of 
40,000-44,000 have been reported. Some assessment of the conformations 
of the protein has been obtained from optical rotatory dispersion and 
circular dichroism. It has been shown that while the content of oc-helices 
is negligible, a considerable portion (approx. 70%) of the polypeptide chain of 
the native oc1AAGP has assumed ~-conformation.37 
Alpha-1-acid glycoprotein is distinguished from other plasma proteins 
in its composition and properties. It is unique for: 
1) High carbohydrate content, at 40% the highest of the serum 
proteins; 
2) Large number of sialic acid residues, about 12 residues per 
molecule; 
3) Low isoelectric point (about 2.5) which is the lowest in serum 
proteins. This is due to the sialic acid residues, removal of which 
from the protein was found to raise the isoelectric point to 
pH 5.4;38 
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4) The protein is very soluble in water and certain polar organic 
solvents even when it is grossly denatured. It is also soluble in 
!OM urea and 5M guanidine HCl; 
5) Alpha-1-acid glycoprotein is stable even in boiling water. At a pH 
below 4 release of sialic acid residues takes place but no 
precipitation of the protein occurs. 
1.3.3.2 The biological role of alpha-1-acid glycoprotein 
The normal serum level of oc1-acid glycoprotein is 75-100mg/ 
100mls. This represents only 1% of the total serum proteins and it is sixty 
times lower than albumin level in the plasma. In certain disease states, 
many plasma proteins increase in concentration as a group, called acute 
phase reactants, which include a number of occ and oc2-globulins. The 
plasma concentration of oc1AAGP more than doubles after surgical trauma 
and also increases in inflammatory conditions, rheumatoid arthritis and 
some malignancies including cancer. A normal individual who undergoes a 
major operation also produces an increased plasma concentration of this 
protein until the wound is healed. However, the function(s) of the 
increased levels of oc1AAGP and the other globulins in these disease states 
are not yet established. 
1.3.3.3 Interaction reactions of alpha-1-acid glycoprotein 
Alpha-1-acid glycoprotein is known to interact with calf thymus 
DNA, to influence blood clotting mechanisms and to inhibit the 
' 
hemagglutination by influenza virus. More important is the interaction of 
this protein with some keto steroids and also more recently with basic 
drugs. 
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1.3.3.4 Steroid-oc1 acid glycoprotein binding 
Westphal and his coworkers have studied the binding of 
/l 4-3-keto steroids to oc1AAGP?' The steroids studied, which were 
progesterone, cortisone, corticosterone and oestradiol, bind at a single 
primary binding site with high affinity (Ka approx. 106M-1). Other binding 
sites of lower affinity were also detected. Competition at the primary 
binding site was observed between progesterone and the other steroids 
except oestradiol which didn't seem to share a binding site with the others. 
So far these steroids appear to be the only endogenous organic substances 
known to bind oc1AAGP with high affinity. 
1.3.3.5 The binding of basic drugs to occacid glycoprotein 
Numerous reports appeared recently which revealed the 
importance of oc1 AAGP in basic drug binding in plasma. Piafsky et al. 
40 
have observed the increased plasma protein binding of propranolol and 
chlorpromazine as mediated by disease-induced elevation of plasma 
oc1AAGP. Increased plasma binding of quinidine after surgery, even when 
the albumin level was decreased, was found to be due to raised level of 
oc1AAGP.
41 Borga42 also found that the plasticiser tris (2-butoxyethyl 
phosphate) TBEP, present as a contaminant in plasma collected in 
vacuitainer, was a potent inhibitor of much basic drug binding to plasma. 
TBEP selectively binds to oc1AAGP in plasma. Raised levels of free drug 
was due to the displacement of basic drugs by TBEP from the oc1AAGP 
binding site. Jackson et a1.43 studied the effect of altered concentrations 
of proteins, accompanying malignant diseases, on basic drug binding. The 
binding of lidocaine was increased even though the concentration of 
albumin was decreased. The increased binding was attributed to the 
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increased concentration of oc1 AAGP. On the whole, these reports and 
several others revealed a significant increase in basic drug binding with an 
increase in the concentration of oc1AAGP, even when the albumin level in 
the plasma was decreased. The average plasma level of oc1AAGP is rather 
low. Therefore, a fairly strong basic drug binding to this protein has to be 
assumed if variations in its plasma concentration were to contribute so 
considerably to the free fraction of the basic drugs in the plasma. These 
clinical findings prompted studies to characterise the binding of basic drugs 
to the oc1AAGP. So far only a few of such studies have been carried out. 
For most of the basic drugs studied, some of which are given in Table 1.1, 
there appears to be one strong binding site on the oc1AAGP. Association 
constants of (103 - 106M-1) have been reported. 
Table 1.1 Basic drug-(X1AAGP binding 
Drug Reference 
Propranolol 44 
Tricyclic antidepressants 
Alprenolol 
Amitriptyline 
Phenothiazine neuroleptics 
Quinidine 
45 
45 
46 
47 
48 
( -\.oL .. 
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1.3.4 The Significance of Drug-Protein Binding Measurements ) u ./1'. . \! .. -~ 
The information obtained from binding measurements (binding 
affinity constants, number of binding sites and the nature of the binding 
sites) provide a broad foundation for understanding the theoretical and 
practical aspects of drug binding to proteins. The roles of the different 
proteins involved in the binding can also be defined. 
21 
Numerous techniques and methods have been used to study the 
interaction between drugs and proteins. Since different methods do not 
have the same sources of error a binding isotherm obtained by one 
technique is not necessarily the same as that acquired by another method, 
which results in differences in the values calculated for the same binding 
system. Different methods of data analysis may produce values that do 
r~ 
vary slightly. Furthermore binding data can be influenced by factors such 
as the concentration of protein, pH, temperature and the concentration of 
salts in the solutions studied. Even different batches of the same protein, 
treated in the same way, produce different binding parameters: therefore, 
rather wide limits have to be accepted when binding results obtained in 
laboratories are compared, before the conclusion of significant differences 
is drawn. 
The vast majority of studies reported on drug-protein binding are 
in vitro investigations. However the manner in which a drug is handled by 
the body is different from the in vitro situations. At times, drug 
concentrations studied in vitro are higher than therapeutic or toxic 
concentrations expected in in vitro situations. Often isolated proteins are 
considered by themselves and the calculation of the kinetics based on pure 
systems alone may poorly reflect the in vivo events that involve 
competition between multiple drugs and metabolites and endogenous 
substances in a variety of protein-containing compartments in vivo. Also 
the competition does not always lend itself to classical mass action 
equilibrium kinetics which is assumed for in vitro studies. 49 In vivo, the 
real milieu for drug-protein binding involves not only the differences 
between the intravascular, extravascular and the intracellular constituents 
considered as compartments of solutions, but also the considerable 
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differences in the make up and reactivity of surfaces of cell and organelle 
walls. 49,50 
Complexities in interactions, unknown to in vitro studies, do arise 
in the body which radically alters the binding . phenomenon not only 
quantitatively but in direction and quality also. The protein may be altered 
such that it changes its binding behaviour. For example, induction or 
sensitization to future binding as a result of prior encounter with a drug 
may influence the conformation of a binding protein to a more active 
shape. A drug, or perhaps a drug protein complex, may influence the 
protein-synthesizing machinery in such a way that it induces synthesis of a 
more or less specific, if not a greater or lesser amount, of a particular 
binding protein. 
Despite the variations in results, in vitro studies have provided, 
and continue to provide, valuable information on drug-protein interactions. 
It is still the keystone to the understanding of the behaviour of drugs even 
in Jiving animals. However, in attempting to apply the in vitro findings to 
drug kinetics in vivo, the complexities involved need to be examined and 
investigated. A large body of knowledge has also developed on the 
interpretation of drug-protein interaction in vivo, as related to in vitro 
situations. 
1.4 Methods for Studying Drug-Protein Binding Interactions 
Characterisation of a binding equilibria involves the determin-
ation of concentrations of components of the equilibrium system; that is, 
the concentrations of protein 'B', free ligand 'L' and complex 'BL' at 
equilibrium shown in equations 1 and 2. 
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A vast array of physicochemical methods have been used to study 
the binding of small molecules (ligands) to proteins. The choice of method 
depends on the concentration of which component(s) at equilibrium is to be 
determined. Each of the techniques used depends on the following 
procedures: 
a) Determination of the concentration of free non-bound 
ligand; 
b) Detection of a change in a physicochemical property of the 
binding protein or ligand. 
In methods that belong to the first group, usually, the protein-
bound drug amount cannot be measured directly but is calculated as the 
difference between the unbound and the total amount of drug in the 
equilibrium mixture after a physical separation of a protein-free fraction 
from the mixture. The methods are therefore heterogeneous. Several 
techniques and methods exist in this category, referred to as classical 
methods. In general these methods differ only in the physical separation of 
the relatively large particles of protein and the complexes from the 
relatively small free drug molecules. 
The second group of methods are the spectroscopic techniques 
which often do not require physical separation of the unbound from the 
Cl<\~«:>.~ 
bound drug forms,~ therefore referred to as homogeneous. Various 
techniques are available, which can be used for drug-protein binding 
studies, and the common ones are listed below: 
Ultraviolet-visible absortion spectrometry; 
Fluorescence spectroscopy; 
Optical rotatory dispersion and circular dichrosm; 
Nuclear magnetic resonance; and 
Electron spin resonance. 
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some of these methods, however, have not gone further than mere 
introduction of the possibility of their application in drug-protein binding 
studies. 
Both classical and spectroscopic methods also lend themselves to 
the study of protein binding displacements in competitive interactions. 
1.4.1 Classical Methods 
In 'these methods, the separation is accomplished by the use of a 
barrier or membrane that has pores large enough to allow the passage of 
drug molecules but not enough to allow the passage of the large protein 
molecules or their complexes. The methods commonly used are: 
Equilibrium dialysis; 
Ultrafiltration; 
Gel filtration; 
Separation using microparticles; and 
Partitioning in two-phase system. 
1.4.1.1 Equilibrium dialysis 
The protein solution is separated essentially by a semi-permeable 
membrane from the protein free buffer solution. Only free drug crosses 
l::he. ~t\c.e.~~o.\:.\..ol'\. ()~ 
the membrane and after an equilibration period}..free drug in the buffer 
compartment (dialysate) will equal that in the macromolecular protein 
solution (retentate). By measuring the ti:I\:Al drug concentration on either 
side of the membrane, the amount of drug bound can be obtained by 
subtraction from the total drug added to the reaction mixture. 
In drug-protein binding, the actual binding process is usually very 
fast and occurs within a fraction of a second but the equilibration, which is 
brought about by diffusion under a concentration gradient of the free drug 
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across the membrane, is a very slow process. The convenient laboratory 
procedure for many years involved the placing of a short length of sausage 
casing (made of ce~phane) tied at both ends that contained the retentate 
in a container of buffer solution (the dialysate) and stirring for as long as 
10-20 hours. Over the years, the efficiency of dialysis has been 
progressively improved by increasing surface area of the membrane to 
volume ratio and by stirring the solution continuously to maintain the 
concentration gradient across the membrane always as high as possible. 
The ultimate aim was to reduce the time required for equilibration. There 
are numerous laboratory procedures designed for better efficiency and 
several designs are available commercially but the method still remains a 
slow one. 
A remarkably different application of dialysis for small molecule-
protein interaction has been devised by Colowick and Warmack. 51 In their 
method the dialysate passed as a flow through the dialysing system, and 
effluent of the dialysate was collected for analysis. The method is based 
on the fact that the usual chemical equilibrium can be reached within a 
very short time and that the rate of dialysis is proportional to the 
concentration of the dialysable species in the retentate compartment 
which contained both the protein and the total drug added. 
Unlike the conventional dialysis, this method is relatively fast. 
However, sensitivity is very low because the rate of dialysis is very low. 
Apparently only about 0.1% of the free ligand passes into the dialysate 
chamber per minute. 
Equilibrium dialysis is the most commonly used method in drug-
protein binding studies because it is simple and inexpensive. Additional 
advantages are the possibility of producing a system which approximates 
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the in vivo conditions, and the thermodynamic validity of the results as 
equilibrium conditions are always restored and undisturbed. 
A major disadvantage is in the long equilibration period and the 
consequent problem of drug degradation, protein denaturation, micro-
biological growth and lipolysis (fatty ester hydrolysis). Sizeable volume 
shifts, which is the net movement of water caused by the osmatic effect of 
the macromolecular solution, results in dilution of the retentate solution. 
There is also the need to perform many separate dialysis experiments to 
obtain sufficient binding measurements and this proves very tedious. The 
more rapid dynamic method such as that of Colowick and Warmack, which 
offers speed at the expense of sensitivity, is not a popular alternative. 
Other disadvantages include the uptake of drug molecules by the 
membrane. 
1.4.1.2 Ultrafiltration 
This involves the separation of a protein-free solution by 
expressing a sample of the reaction mixture through a se m !permeable 
membrane by the application of either a positive pressure, for example 
from a compressed nitrogen source52 or by centrifugation. A negative 
pressure from a vacuum has also been used. 53 A rapid micro ultrafiltration 
technique for drug binding in small volumes of plasma was also developed54 
by adapting the ultrafiltration chamber to accommodate and permit 
filtration of very small volumes. This method permits the use of only one 
tenth of the volume of solution required for conventional ultrafiltration. 
So far, ultrafiltration has been used for only a few studies of 
drug-protein binding. Spector et al. 55 measured salicylate binding to 
plasma proteins. Danon and Sapira56 studied the binding of catecholamines 
to serum albumin. Campion and O!sen57 have used the continuous 
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ultrafiltration technique to study the displacement of sodium urate and 
methyl orange by salicylate from human serum albumin. The micro 
ultrafiltration technique .has been used to determine the binding of aceta 
zolamide, diphenylhyadantoin and salicylic acid in undiluted human54 
plasma. 
The principal advantages of these methods have been the economy 
of time and material when eompared to equilibrium dialysis. Separation is 
achieved in a matter of minutes. Eeonomy of material is desirable in drug-
protein binding studies. 
Even though most of the data obtained so far by ultrafiltration do 
agree with those obtained by equilibrium dialysis, its application in this 
field has been scanty. There are generally recognised limitations of the 
method which are: 
(1) Polarisation of protein on the membrane which results in 
increased loeal coneentration of protein just over the 
membrane;58 
(2) The uptake of drug molecules by the membrane; 
(3) The change in concentration of protein due to removal of 
filtrate, which also disturbs the equilibrium by the removal 
of the free drug filtrate from the sample; 
(4) Influence of filtration on pressure in selectively altering the 
transport of solvent and drug molecule has been realised by 
some workers. 59 Dilution of the ultrafiltrate is observed at 
higher filtration pressures. 
Polarisation of protein can be minimised by efficient stirring. The extent 
of membrane binding can be assessed by independent experiments. 
Reeently Whitlam et al. 60 presented a theory which accounts for the 
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observed dilution of ultrafiltrate at higher filtration pressures. Mathem-
atical simulations by these workers showed that the ultrafiltrate 
concentration remains constant during filtration. This finding greatly 
extends the value of the ultrafiltration technique in drug-protein binding 
studies and is yet to be appreciated. 
1.4.1.3 Gel filtration 
Separation in gel filtration is achieved on the basic principle that 
gel particles are permeable to small molecules but not to macromolecules. 
Passage through the gel column separates small molecules which penetrate 
the gel particles as well as the column space from the macromolecules, 
which are excluded from the gel particles. The macromolecules are hence 
eluted first, sometimes at the void volume of the column, while the small 
molecules elute much later at the salt volume of the column. 
Gel filtration was first adapted by Hummel and Dreyer61 for the 
measurement of the concentration of free drug at equilibrium with a 
protein. Danon and Sapira62 have applied this method to study the binding 
of 14c-labelled catecholamines. In gel filtration several hours are 
required for an average run, but faster than the conventional equilibrium 
dialysis. However, it can be slower or more tedious when a whole binding 
isotherm is required. Specific interactions with the gel, together with 
difficulties in correctly calculating the binding constant from results 
obtained as trough and peak areas, have precluded its application in 
general. 
1.4.1.4 Determination of binding characteristics 
using microparticles 
It is well known that proteins such as enzymes, immunoglobulins 
and albumin retain their biological properties when immobilised in 
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microparticles of highly cross-linked polyacrylamide. 63 Kober et al. 64 
have studied the binding· of salicylic acid, warfarin and tryptophan to 
albumin immobilised in microparticles of polyacrylamide. Essentially, the 
immobilised protein, which is only physically entrapped in the micro-
particle suspended in buffer, is mixed with a known concentration of the 
drug. Equilibration is attained rapidly within. minutes, and the 
concentration of free drug is obtained from the supernatant after 
centrifugation. 
This procedure is barely known in the field of drug-protein binding 
studies. It is simple and more rapid than the normal gel filtration method 
and the extent of binding can be determined more accurately. However, 
the precision and applicability of this method needs further testing and 
investigation. 
1.4.1.5 The determination of binding characteristics by 
partitioning in a 2-phase system for separation 
Partitioning in aqueous two-phase systems has also been used 
recently for the separation of bound and free ligand. A phase system was 
chosen to give partitioning conditions with the free and bound ligand in 
different phases. The interaction between serum albumin and Cibacron 
Blue F3G-A was used as a model system. 65 The protein partitioned to the 
bottom phase and the ligand to the top phase in a phase system consisting 
of poly(ethylene glycol) and dextran. 
This technique is simple and fast and has proved useful in 
immunoassays. 66 It has been applied to steroid protein interaction67 but 
the applicability to drug-protein binding seems not to have been explored 
and the limitations need to be evaluated. 
-I 
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1 1.4.1.6 Determination of free drug 
Various methods of determining the concentration of the unbound 
drug could be used regardless of what method is used for the separation. 
For those drugs that absorb strongly in the ultraviolet-visible region, 
absorbance measurement was used. However, this method often lacks the 
required sensitivity. Radiolabelled drugs are commonly used for the 
required sensitivity in drug-protein binding studies but at the expense of 
radiation hazards and costly reagents. Other spectroscopic methods have 
been used also, but less frequently, in determining the separated unbound 
drug. 
1.4.2 Spectroscopic Methods 
There are various spectroscopic techniques available and used for 
ligand-macromolecule binding studies. Binding of a ligand to a 
macromolecule is often accompanied by a change in the spectroscopic 
property of the ligand or the macromolecule. The extent of the change is 
often a measure of the bound ligand or macromolecule. In this group of 
methods no separation of the bound from the free species is required, and 
the methods are classified according to the spectroscopic property used to 
measure the binding. 
Compared to the classical methods available, spectroscopic 
methods have a number of distinct advantages: 
(1) They are much more rapid than most of the classical 
methods because no separation step is required and the 
consequent effects of long periods of equilibration is 
eliminated. 
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(2) Measurements are performed on the whole reaction mixture; 
that is, the drug-protein complex in contact with the free 
drug and the protein at equilibrium. 
(3) They can also yield information on the nature of the drug-
protein interactions. For example, changes in the 
ultraviolet or visible absorption spectrum of a drug may be 
interpreted in terms of the polarity of the drug binding site. 
Nuclear magnetic resonance spectroscopy (NMR) often 
indicates which groups or parts of a drug molecule are 
involved in the binding process, whereas optical activity 
may yield information on the three-dimensional structure of 
the binding sites. Fluorescence characteristics which are 
sensitive to changes in the microenvironment of the drug 
molecule may change on binding. 
Most spectroscopic techniques are suitable for drug protein 
binding studies. Of these methods only the corn m only used ones will be 
discussed. These are (NMR), optical activity and fluorescence methods. 
1.4.2.1 Nuclear Magnetic Resonance (NMR) 
Nuclear Magnetic Resonance is an attractive method for the 
study of drug-protein binding because in addition to the study of the 
dynamic aspects of the binding, it offers a unique range of information 
about the environment, structure, and rotational restriction of the drug, 
when it is bound to the protein. 
When a drug is bound to a protein, the relaxation characteristics 
c:\.TWj'.5 
of one or more of tM~-atoms, or one or more of those of the protein, may 
be altered. This alteration may show up as a "chemical shift", a frequency 
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change, or as the broadening of a line in the proton magnetic resonance 
spectrum. Selective broadening of some of the proton resonance of the 
small molecule is always observed when it is bound to a protein and has 
been interpreted as a sign of intimate contact between such protons, or the 
groups to which they belong, and the protein. Chemical shifts arise from 
rapid reversible changes of the state of the ligand from bound to unbound 
and reflect not only the shifts in the nucleii which are caused by binding, 
but also the time average of the fraction of the drug bound. 
Observation of the line-broadening has been used by Fischer and 
Jardetsky68 to study the binding of penicillin G and also by Jardetsky and 
Wade-Jardetsky69 to study the binding of sulphonamides to bovine serum 
albumin. Sykes and Hun70 have studied the binding of acetyl salicylic 
acid to human serum albumin by the study of the observed chemical shifts 
on NMR spectrum. 
The main disadvantage of NMR for drug-protein binding studies is 
the intricate nature of the spectra produced and small changes are often 
observed, hence the sensitivity is very low. An important practical 
disadvantage is that the stoichiometry of the binding is unavailable from 
the measurements and must be obtained from other techniques. ' ', , 
1.4.2.2 Optical rotatory dispersion (ORD) and 
circular dichroism (CD) 
When a small molecule binds to a protein, changes in secondary, 
tertiary or quarternary structure may result, that can often be detected as 
a change in the ORD or CD spectrum of the protein. The wavelength, 
magnitude and character of these changes indicate ligand-induced protein-
conformational changes. It has been found that the binding of several 
anionic azo dyes altered the specific rotation of human serum albumin, / 
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with the strongly absorbing dyes causing the largest deviations. 70 ~" 
Methods involving changes in the intrinsic optical activity of the drug 
fl\Olecule are also applicable to those drugs that are optically active, 
particularly those of natural origin. So far this method has not proved its 
usefulness in drug-protein binding studies. A large number of molecules, 
including dyes and drugs that are optically inactive, become active when 
bound to certain proteins and produce extrinsic cotton effects. These 
effects are observed when certain acidic drugs bind to serum albumin. For 
example, the binding of dicoumarol, phenylbutazone and flufenamic acid to 
human serum albumin produced cotton effects suitable for binding 
studies.11 <' "Bilirubin-also._p@J!gLSI.Igh __ effects 72_when .. bound-to- human 
serum albumin, 
On the whole, the use of ORD and CD for drug-protein binding 
studies has been limited in the way of quantitative estimation of binding 
characteristics. More on the three-dimensional structure of the binding 
r sites and the conformation of the protein is gained from these methods. 
"' _./ 
1.4.2.3 Fluorescence 
The application of this technique to the study of small molecule 
binding to a macromolecule has been extremely successful for both 
qualitative and quantitative characterisation of the binding. The 
fluorescence of the small molecule can be drastically altered when it binds 
to a macromolecule. Similarly the fluorescence characteristics of the 
macromolecule can be modified by the binding. When such changes occur 
it is possible to measure the extent of binding and to gain information about 
the nature of the interaction. If neither the small molecule nor the 
macromolecule possess suitable fluorescence characteristics, the inter-
action can often be examined with the use of a fluorescent label.6 In order 
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to understand the versatility and the various applications of this technique 
to drug-protein binding studies an . understanding of the theory of the 
technique is necessary. 
1.4.2.4 The theory of fluorescence 
Fluorescence is the rapid emission of light energy from a 
molecule which has become exCited by light absorption. In order to 
fluoresce, therefore, a m·olecule must absorb light. By absorbing energy 
the molecule is raised to a higher energy level where the pair of electrons 
still revolve in an opposite direction, in a singlet state (s state in Fig. 1.2). 
Excitation is initially to the s1 state.· Higher excited singlet states s2 and 
s3 can also be occupied but decay rapidly in about 10-
12s to the s1 state. 
Fluorescence emission, with an average life time of about 10-8S, occurs 
always as a result of transition from the s1 state to the ground state s0• 
As shown in Fig. 1.2, fluorescence emission competes with non-
radiative processes with compatf!ble rate constants. Hence fluorescence 
power emitted is rarely 100% of the absorbed radiation power. The main 
competing processes are: 
(1) Intersystem crossing whereby the excited molecule goes to 
the triplet state T 1 by a non-radiative spin inversion 
process; 
(2) Internal conversion which is the spontaneous decay to the 
ground state by a non-radiative process; 
(3) Energy transfer from the excited state to another molecule 
may occur, which may either be fluorescent or not. 
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Figure 1.2 Competitive processes affecting a molecule in an 
excited state s1• Straight lines- radiative transitions; Wavy 
lines -· non radiative transitions; s0 - Ground state; s1 -
Lowest excited singlet state; s2 and s3 - higher excited 
singlet state; 
Rate constant of internal conversion; 
Rate constant for intersystem crossing; 
Rate constant for fluorescence; 
Lowest triplet state; 
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(4) Photodecomposition whereby the excited molecule under-
goes chemical reaction to yield a product. 
The lifetime of an excited state is sufficiently long for a variety 
of chemical and physical interactions to occur prior to emission. The 
interactions include: 
(1) Change in optical rotation 
A*===;;: A'* 
(2) Solvent reorientation 
A*.:===;: A'* 
(3) Complex formation 
A* + B AB* 
(4) Proton transfer 
A* A-* ~ + 
or 
A* 
(5) Cis-trans isomerisation 
trans- A* ~ Cis- A* 
These interactions with the excited molecule produce various changes in 
the observed fluorescence of the molecule. These include changes in 
fluorescence spectra, quantum yield, intensity, fluorescence polarisation 
and decay time. 
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1.4.2.5 The ligand-protein binding and fluorescence changes 
When a ligand binds to a protein covalently, or non-covalently, 
changes may occur in the molecules themselves, or their surroundings, 
which can alter their fluorescence characteristics. There can be some 
effect from the change in chemical structure when the reactive functional 
group on the ligand eliminates some groups on the protein by combining 
with it. It may be the effect of hydrogen bonding or electrostatic 
interactions. More important in non-covalent binding, is the fact that the 
nature of the surrounding environment in which the molecule now finds 
itself is different from that of its free state in the solvent. Another 
feature of the environment may be that the molecule becomes fixed to the 
protein and hence can no longer move about independently as it would in 
the unbound state. 
To explain the fluorescence changes observed when a ligand binds 
to a protein several electronic mechanisms have been invoked which 
include the following : 
(1) A change in the ionisation either of the ground state or of 
an electronically excited state. 
(2) Electronic energy transfer by a type of resonance 
mechanism. In resonance transfer, the energy of the 
excited donor molecule is lost via transfer to the acceptor 
without any emission of radiation or collisional contact 
between the donor and acceptor molecule. For resonance 
transfer to occur, maximum spectral overlap between donor 
emission and acceptor absorption is an important pre-
requisite. It also depends on the relative orientation of the 
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donor and acceptor molecules. The transferred energy may 
be lost by the acceptor molecule by a non-radiative 
mechanism or may be emitted as fluorescence at the 
acceptor molecule's wavelengths. 
(3) A change in the rate of intersystem crossing. This 
transition from the singlet (s1} state to the triplet (T} state, 
as noted by workers, is favoured by an increase in the 
polarity of the medium. 73 That is, hydrophobic interaction 
which reduces the polarity of the microenvironment of a 
fluorescing ligand on binding, will decrease the rate of 
intersystem crossing. 
(4) A change in the rate of internal conversion. This process is 
!Jsually favoured in molecules that have large numbers of 
vibrational states. Internal conversion may either be more 
or less favoured in a bound molecule as evidenced by 
quenching or enhancement. 
(5) Reabsorption effect on fluorescence yield (inner filter 
effect) may be similar to that of energy transfer, but in this 
case the ligand molecule absorbs the radiation emitted by 
the protein molecule resulting in the quenching of the 
protein fluorescence. 
The effects of the binding on fluorescence characteristics have 
been corr-elated with such macroscopic quantities as the dielectric constant 
or the Kosower Z parameter, which is an empirical measure of solvent 
polarity. 7 4 Hence the effect of binding can also be described as, or· in 
terms of, changes in the amount of hydrophobic, and hydrogen, bonding. 
The accessibility of large ions such as iodide may also lead to deactivation 
of the excited state. 
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1.4.2.6 The effect of environment on the fluorescence of a molecule 
The fluorescence of a molecule depends on several properties of 
the environment. Molecules with greater dipole moments in the excited 
state than the ground state, show solvent-dependent emission character-
istics, Other molecules may be sensitive to the proton-donating or 
lhe. 
accepting character of the solvent. A -fluorescence of some molecules 
depends on the viscosity of the solvent. 
The fluorescence of several dye molecules has been characterised 
in a large number of solvents and solvent mixtures. 75 Generally, a transfer 
of the dye molecule from a non-polar to a polar solvent results in a red 
shift in the fluorescence emission spectrum, an increase in the bandwidth 
and a precipitous drop in the quantum yield, In contrast to the large 
solvent effects ol"- 'tile fluorescence, t*le absorption shows only a small 
dependence on the solvent polarity. 
1.4.2.6.1 The effect of solvent on the emission spectrum 
The dependence of the emission spectrum on solvent can be 
understood on the basis of a theory advanced by Lippert, 75 independently 
by Mataga, 76 and also reviewed by Brand et al. 79 If the dipole moment of 
the excited state is greater than that of the ground state, solvent 
molecules can relax around the excited state, prior to emission. This will 
tend to lower the energy of the excited state resulting in a red shift in the 
fluorescence emission spectrum. This process is illustrated in Fig. 1.3 and 
described by the following equation; 
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Figure 1.3 A transition state diagram showing solvent relaxation 
and intersystem crossing. Fluorescence after solvent 
relaxation F' is of lower energy than F. Intersystem crossing, 
ic, is also more favoured after solvent relaxation. 
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V A is the wavenumber (cm - 1) of the lowest energy absorption 
maximum, 
VF is the wavenumber (cm - 1) of the fluorescence maximum, 
h is thE Planck's constant, 
C 0 is the speed of light, 
E is the static dielectric constant of the solvent, 
n is the refractive index of the solvent, 
Me is the dipole moment of the first excited state of the solute 
molecule, 
Mg is the dipole moment of the ground state of the solute molecule, 
and 
a is the radius of the Onsager cavity 77 for the solute molecule in 
question. 
This equation is valid only if there is sufficient time for the solvent to 
relax prior to emission. 
For a large number of dye molecules the blue shift observed when 
bound to proteins is due to this phenomenon. 
1.4.2.6.2 The effect of solvent on bandwidth 
McClure and Edelman 78 have suggested that the solvent 
relaxation, increasing the interaction of the chromophore with the solvent, 
would result in an increased number of vibrational levels in the excited 
state. culminating in tile emissiaR. This would account for the decrease in 
bandwidth observed in non-polar solvents or protein binding sites, 
1.4.2.6.3 The effect of solvent on quantum yield 
Many dyes show several fold GF many fold increase in 
fluorescence when transferred from a polar to a non-polar solvent or when 
42 
bound to proteins. With the majority of solvent systems the changes in 
quantum yield parallel the changes in emission maximum, It thus appears 
that a common mechanism is involved. An explanation for the quenching 
observed in polar solvents have been advanced by several workers as 
reviewed by Brand et al. 79 The dipole moment of the first triplet state, 
T 1' is expected to be less than that of the first excited state, sl' therefore 
solvent relaxation would be expected to decrease the singlet-triplet energy 
split, facilitating intersystem crossing, thereby quenching the fluorescence. 
For a protein-bound dye molecule or in the case of non-polar solvents, this 
energy split is much larger which favours fluorescence transitions rather 
than intersystem crossing. Hence, a fluorescence enhancement is observed 
when dye molecules bind to proteins. 
While the explanation above appears to account for the general 
effects on the quantum yield, a variety of specific quenching mechanisms 
may be significant and do often contribute to the observed effects of 
quantum yield. 
1.4.3 Fluorescence Methods for Drug-Protein Binding Studies 
Fluorescence methods for the measurement of binding equilibria 
depend on the change of a measurable parameter of the drug-protein 
system with binding. The parameter most commonly used is fluorescence 
intensity, and less often fluorescence polarisation is used. For the binding 
system to be amenable to fluorescence measurements the following 
conditions need to be satisfied: 
(1) The change in fluorescence should be rapid relative to the 
binding process so that the only time dependent process is · 
the actual binding. 
i 
j 
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(2) The association constant of the drug must be high enough 
for a readable fluorescence signal with the common 
fluorimeters and also for the lowest concentration of 
protein solution that can be handled without denaturation. 
(3) The fluorescence changes incurred on binding must bear a 
quantitative relationship to the measure of the binding; that 
is, the product formed, or the reactant used up. 
1.4.3.1 Drugs that alter the intrinsic fluorescence of the protein 
When a drug molecule binds to a protein, fluorescence quenching 
of the protein is sometimes observed. Several workers have studied the 
binding of drugs and endogenous species to proteins by their quenching 
measurements, some of which are given in Table 1.2. Foster80 showed that 
the fluorescence quenching is predominantly a result of resonance transfer 
of energy from the protein to the bound drug. For many drugs and 
endogenous species an appreciable overlap exists between their absorption 
spectrum and the protein emission (320nm-350nm for tryptophan 
containing proteins and 305nm for proteins that lack tryptophan). 
Table 1.2 Proteins that show fluorescence changes on 
interaction with drugs and endogenous species 
Ligand Protein Reference 
Dansyl sulphonamide Carbonic anhydrase 81 
Sulphonamide 11 82 
Warfarin Serum albumin 83 
Dicoumarol 11 83 
Flufenamic acid 11 84 
Progesterone 11 85 
Thyroxine 11 86 
Bilirubin 11 87 
Chlor~romazine Myosin 88 
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The quenching method is also applicable to the measurement of 
competitive interactions provided the binding of only one of the drug 
molecules quenches the protein fluorescence. 
1.4.3.2 Problems with inherent protein fluorescence I 
Protein fluorescence, which is due to a number of residues 
arranged differently in the intricate macromolecule structure and 
conformation, is a complex one.9Q When a ligand binds to a protein, the 
fluorescence yield changes may not always be proportional to the number 
of ligands bound. Unless each ligand molecule is binding to an identical 
subunit, the tyrosines and tryptophans {amino acid residues responsible for 
protein emission) may be arranged, and thus quenched, differently. Even if 
each ligand is binding to an identical subunit, its quenching radius may 
reach into adjacent subunits such as to make the environments on the two 
sites of the subunits different. Non-linear quenching may also be a result 
of overlapping quenching volumes. Another cause is the occurrence of 
some conformational change on binding, which might perturb previously 
identical environments to different extents. 
1.4.3.3 Drugs that change their intrinsic fluorescence n 
when bound to proteins 
When a drug itself undergoes a change in fluorescence on binding 
to a protein, the change in the fluorescence characteristics of the drug is 
used to study the binding. The most useful change for the quantitative. 
estimation of the binding is the change in quantum yield or fluorescence 
intensity. 
Several workers have reported the use of this method for the 
estimation of drug-protein binding parameters1some of which are given in 
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Table 1.3. Chen and Kernohan"1found that while the fluorescence of free 
dansyl sulphonamide (DNSA) in water had a peak emission at 580nm and a 
quantum yield of 0.055, when bound to carbonic anhydrase, the emission 
maximum moved to 468nm and the quantum yield increased to 0.84. A six 
fold increase in the fluorescence quantum yield of warfarin was also 
observed when it binds to human serum albumin while tetracycline showed 
a ten fold increase in its quantum yield when bound to bovine serum 
albumin. All the changes in fluorescence observed were explained by 
energy transfer from the protein to the drug molecule and also polarity 
effects at the hydrophobic protein binding sites. 
Table 1.3 Drugs and other ligands that change their 
fluorescence yield on binding to proteins 
Drug Protein Reference 
Dansyl sulphonamide Carbonic anhydrase 81 
Warfarin Serum albumin 83 
Hapten Antibody 89 
Tetracyline Bovine serum album in 91 
1.4.3.4 Fluorescent probes for binding studies 
If neither the drug nor the protein has suitable fluorescence 
properties, a drug-protein binding can still be studied by complexing 
(covalently or non-covalently) the protein with a fluorescent label. These 
labels are usually small molecules of known chemical structure. 
Covalently attached labels are often used for structural investigations of 
I 
proteins and in many immunoassays. In drug binding studies, the non- , j 
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covalently attached labels are often employed. The non-covalently 
attached label which undergoes changes in one or more of its fluorescence 
properties as a result of binding to a protein or other macromolecule is 
termed a fluorescent probe. This definition applies to the drugs themselves 
which change their intrinsic fluorescence properties on binding to a 
protein. 
There are many labels available for non-covalent attachment to 
'?;~ . 
proteins, as discussed in a review article:'79'" The most popular of these are . 
1-anilino naphthalene-8-sulphonic acid (ANS), 2-p-toluidinylnaphthalene-6- · 
sulphonic acid (TNS) and 5-dimethylaminonaphthalene-1-sulphonyl (dansyl), 
derivatives of amino acids such as glycine. These compounds, whose 
"' \> <. t A. <'\ I .·•, ·~·"'~.<} VV· '"- '· ':J .. J • 
structures are given in Table 1.4, show a marked increase in their 
fluorescence quantum yield and a blue shift in their emission peak, when 
bound to proteins such as serum albumin. This property, which is due to 
their sensitivity to polarity, forms the basis of their wide use as probes in 
protein binding and other investigations. 
Fluorochromes that are sensitive to other physical and chemical 
phenomena are also beginning to emerge. For example, aromatic alcohols 
have been used to investigate the proton accepting character of the 
immediate environment at the chromophore binding site. 92 There are 
other dyes, for example auramine 0, whose fluorescence depends to a large 
extent on the microviscosity of the environment. 93 Probes like 
pyrenebutyrate, whose fluorescence is quenched by oxygen, fluoresces · 
when bound to bovine serum albumin. 94 The albumin offers protection . 
against the oxygen molecules. 
Several fluorescence probes have been used, particularly the 
polarity probes, for structural and conformational studies of macro-
---------------------------------------------------------------------, 
Table 1.4 
I 
The structure of some common 
fluorescent labels 
1-anilino-8-naphthalene Q.C.lCl 
sulphoni.c.A (1, 8 ANS) 
Dansyl glycine 
H 
N 
2-p-Toluidinonaphthalene 
c..c.\.0. . 
-6-sulphoni.c. A (2, 6 TNS) 
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molecules. A few have been used for the study of the polarity of protein 
binding sites among which only dansylamino acids and ANS have been used 
for the quantitative characterisation of drug-protein binding. 
1.4.3.5 Dansyl amino acids and ANS for quantitative 
characterisation of drug-protein binding 
When dansyl glycine binds to a human serum albumin (RSA) the 
quantum yield of the ligand increases five fold, while its fluorescence 
emission maximum moves from 580nm to 480nm. Fluorescence titration 
showed that binding occurs at a single binding site for which the 
association constant is 4.6 x 105M-1• Chignen95 showed that several 
anionic drugs such as phenylbutazone, flufenamic acid and dicoumarol 
competitively displaced dansyl glycine from its binding site on the RSA. 
Such results not only indicate that these drugs have one common 
hydrophobic binding site on the RSA but also permit calculation of their 
association constants from the displacement measurements. Solomon96 
has studied the binding of sulphonamides, naphthalene and p-chlorobenzoic 
acid by displacement measurements. A compound that contained a basic 
group, for example aniline, N,N-dimethyl alanine and p-aminobenzoic acid 
could not displace dansyl glycine from human serum albumin. 96 
ANS is only very weakly fluorescent in an aqueous solution 'j 
(emission and excitation wavelengths 470nm and 370nm respectively) but 
exhibits a shift in the emission maximum and a large increase in 
fluorescence intensity (about a hundred times) when bound to serum 
albumin. The enhancement phenomenon, which permits very sensitive 
measurements, was applied only recently by ~. Miller97 to the study of 
acidic drug binding to human serum albumin. The ANS binds human serum 
albumin at one high affinity binding site (Ka = 4.2 x 106M-1). Two other 
~~--~~~~-------
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weaker binding sites were also detected. Being acidic, ANS could be 7 
displaced from its protein binding site by organic anions. The displacement -
effects of several organic anions including acidic drugs on ANS binding 
have been studied by the same worker. The competitive displacement 
effect was also true of bilirubin and fatty acids. 
1.4.3.6 Fluorescence polarisation in drug-protein binding studies 
For most small molecules in water so much Brownian motion 
occurs that the fluorescence is practically completely unpolarised. Large 
molecules, like proteins, that are relatively stationary show marked 
fluorescence polarisation. Similarly a small molecule, which shows 
virtually no polarisation in free solution, shows a marked increase in 
fluorescence polarisation when bound to a protein. Such a change in 
fluorescence polarisation can be and has been used to detect and study the 
binding of drugs to protein. 
The degree of polarisation, P, is defined as the ratio, 
The intensities Iy and IH are obtained by observing the fluorescence 
through an analysing polariser which is oriented vertically and then 
horizontally respectively. Generally the sample is excited with vertically 
polarised light. 
This technique has been applied by some workers to study the 
binding of drugs to proteins as listed in Table 1.5. 
1.4.3.7 Ideal requirements of a fluorescent probe 
r· k.IU'C .J(,,,_ 
All the• fluorescence methods discussed above share the advantages of 
"--- ~-- .. "·-~---~------ ----··· ·----- ----.-·•0'' - • ·--------- -- ---1i.-~<) 
speed, convenience and sensitivity. All have been applied successfully to 
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drug-protein binding studies. However, the future should see a marked 
increase in the application of fluorescent dyes as probes which can be 
chosen to give the most sensitive and convenient methods of drug-protein 
binding studies. 
Table 1.5 
Drug 
Chlorpromazine 
Chlorpromazine 
Thioproperazine 
Camptothecin 
Drug-protein binding studied by 
fluorescence polarisation 
Protein 
Human serum albumin 
Crab myosin B 
Crab myosin B 
Human serum albumin 
Reference 
98 
88 
88 
99 
Problems with inherent protein fluorescence have been given 
above. Besides this[Pr~~in fluorescence is ofte~_<!orn~!~B.!~d-~ys~~:~.~te£ 
which makes accurate fluorescence measurements impossible. High energy 
·---~-~--------~··· . ---- - . . . --~- -- -----
ultraviolet radiation used.to excite proteins, and also some_ drugs, is likely 
---------- --- - - ' -
to cause photodecomposition, particularly with drugs that are photo-
sensitive. Discrepancies due to non-specific quen~hjng_ effects are also 
more likely at a high frequency radiation •. 
Probes_!hf:ltproduce a large_l!ha!lge_in_fluorescence on binding to a 
•-- • - --·--- -~--v-.-~~----· ·------ ' •' 
erot~Jn, __ such_ as .the ANS, are_ o~ten preferred for higher sensitivity. 
H()\Y_(lyer, in order to succeed, a probe, whether the drug itself or a 
flu()rescent label, is expected to satisfy certain requirements: 
(1) Appropriate affinity so that the complex is fairly dissociable 
and a good percentage of binding is attained at a reasonable 
protein to probe concentration ratio; 
I 
i j 
(2} 
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Specificity which permits measurements in the presence of 
other proteins (a great advantage in plasma samples}; 
(3} Solubility in water and high affinity for the protein 
hydrophobic regions; 
(4} Stability both under measurement conditions and on storage 
so that long-term standardisation of assay procedures can be 
performed; 
-¥·>' 
(5} A good., Stokes' shift (greater than 50nm} to prevent 
\ ' 
interference due to Raman and Rayleigh scatter. Excitation 
and emission should also be as far removed as possible from 
those of protein or plasma background which have emission 
at 340nm and 470nm. The emission maximum requirement 
of an ideal probe is 500nm-700nm. Excitation maximum in 
the visible region avoids ultraviolet irradiation of the 
sample. 
1.5 Quantitative Estimation of Drug--Protein Binding Parameters 
Quantitative information on drug-protein binding can usually be 
obtained from plots of the experimental data. A number of methods for 
graphical and computer-assisted analysis of the binding data are available. 
The plots are devised from various linearised forms of the simple binding 
equation for single non-interacting binding sites. The most common plots 
are the Hill plot100 and the Scatchard method,lOO,lOl,lOZ the latter being 
the most popular. The methods bear a quantitative relationship and are 
thus interconvertible. 
For example, the Scatchard method is essentially based on the 
' i 
' \ 
/ 
52 
relationship between the fraction, R, of macromolecule sites occupied 
by the ligands to the association constant Ka; defined as 
(9) 
or 
= (10) 
[CB = concentration of potential binding sites CB = Cs - CBL] 
the derivation of which is based on equation (2). Various forms of the 
equation are derived, depending on the experimental data available. 
Often the binding system is more complicated than assumed in the 
derived equations. The binding sites may be independent but non-identical 
(different affinities). Cooperative binding, whereby binding at one site 
affects binding at another, is also a corn m on phenomenon. The 
complexities lead to non-linearity in the Hill and Scatchard plots. For 
quantitative interpretation of the binding data, for systems not showing a 
single affinity, various graphical methods have been proposed some of 
which are extracted from the Hill and Scatchard plots.103,104,105 
However, discrepancies occur in the results which could be attributed to 
the imprecisions of the graphical methods. The emergence of computers 
allows models for complicated data analysis with greater precision. The 
results of various graphical methods were then compared103 with the 
results obtained by computers, sometimes taking care not to adopt the 
algorithm of the graphical methods for the computer. Despite the 
extremely powerful methods available in large computing centres,106•107 
difficulties remained. 
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In spite of the various methods used, a given set of binding data 
still contains the same information, independent of the particular method 
used to interpret it. However, certain methods show some aspects of 
binding information more clearly than others. For example, models 
extracted from the Hill plot are preferred for plotting data showing 
positive cooperativity (ligand binding at one site facilitating binding at 
subsequent sites), while the Scatchard analysis is most useful in cases 
which show non-identical binding sites or negative cooperativity (binding at 
a site making binding at subsequent sites less probable), 
For competitive binding, simple equations based on the mass 
action law, are also easily derived. The plots of the equations permit the 
estimation of the ratio of the binding constant, K, of the two competing 
ligands. The basic equation is given below; 
r 
= K 1f (11) 
r and R are fractions of binding sites bound to the two competing ligands, 
the concentrations of which in the binding system, are Cn and CL 
respectively. Various forms of the equation could be derived, depending 
also on the experimental data available, The equation holds only when the 
interaction is purely competitive between two ligands for identical sites on 
the protein molecule. 
Many workers have applied this equation to test for competitive 
inhibition, 2S,10S,109 and for estimating the ratio of the binding 
constants.109 For more complex systems the data analysis is even more 
complicated than the single binding discussed above. 
1.6 The Calcu1atlon of Binding Parameters from 
Fluorescence Measurements 
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Binding parameters can always be calculated from fluorescence 
measurements, provided the fluorescence characteristics of the fully bound 
and the fully free states are known. The change in fluorescence 
characteristic per unit binding must also be constant. 
For a change in the fluorescence intensity of the ligand on 
binding; 
po 
e = 
= 
F: fluorescence enhancement due to fully bound protein complex 
F; fluorescence intensity of the fully bound sample 
(12) 
(13) 
F s fluorescence intensity of the sample at any point of the titration 
Fe fluorescence enhancement at any point of the titration 
F f fluorescence intensity of the free ligand per unit ligand 
concentration 
c• L concentration of ligand added· 
By substitution equation (10) becomes 
= 
F: and Fe are obtained from equations (12) and (13) respectively. 
Also, 
and 
= 
= c• B 
(14) 
----------------------------- ------
F b fluorescence enhancement per unit ligand bound by the protein, 
For competitive binding 
R = = 
r = 
Provided CBD + CBL = CB 
By substitution equation (11) becomes 
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= (15) 
1.7 Luminescence Studies of Alpha-1-Acid Glycoprotein and its 
Basic Drug Binding Properties: Proposed Investigation 
The main intention of this work is to develop fluorescence 
methods for the study of alpha-1-acid glycoprotein and its basic drug 
binding. 
In the first part of the work, the luminescence properties of 
alpha-1-acid glycoprotein will be studied. This will include the effect of 
basic drug binding on the intrinsic fluorescence of the protein. The effect 
of protein binding on the intrinsic fluorescence of some common basic 
drugs, and the possibility of using a drug as a fluorescent probe will also be 
studied. 
The use of basic fluorescence labels as probes for the protein and 
the basic drug binding will be studied. The prime objective will be to find a 
label that: 
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(1) Provides a sensitive, fast and convenient method for the 
evaluation of the basic drug binding characteristics, possibly 
by competitive binding between the label and' the drug and 
also endogenous species; 
(2) Allows the study of the nature of drug binding sites on the 
protein and also to follow conformational changes in the 
alpha-1-acid glycoprotein; 
(3) Binds specifically to alpha-1-acid glycoprotein in plasma; 
The possibility of automating the study by flow injection analysis 
for the binding measurements will be studied. This will include the 
application of gradient PIA for faster titration methods. 
---------------------------------------------------------------------------
Chapter 2 
MATERIALS, INSTRUMENTS AND 
GENERAL PROCEDURES 
2.1 Materials 
Material Source and description 
Labels: 
1-anilino naphthalene-8-sulphonic acid [ANS 1 Sigma Chemical Company Ltd 
Mono dansyl cadavarine 
E-dansyl-L-lysine 
h. 
n 
n 
Cal Biochem Ltd or 
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DL-N -[ 2-hydroxy-3-(1-naP,(thyloxy)-
propyl]-N'-dansylethylenediamine 
[DAPN] Molecular Probes Inc., Oregon, USA 
DL-N' - [ 2-hydroxy-3-(l-naphthyloxy) 
propyl]-N 2- (9-acridyl)-1,2,-
propanediamine [ 9-AAP] 
Serum Proteins: 
Cal Biochem Ltd 
Standard whole human serum Behring Institute 
oc-1-acid glycoprotein (human serum) Sigma Chemical Company Ltd 
Albumin (human serum) Cal Biochem Ltd 
oc-1-antitrypsin (human serum) Sigma Chemical Company Ltd 
Cohn fractions (human serum) 
~-globulin fraction lii 
~-Lipoprotein fraction lll-0 
oc-globulin fraction IV -1 
oc-globulin fraction IV-4 
P-L Biochemicals 
n 
n 
n 
Continued •.• 
Material 
Rabit immunoglobulins 
to human serum 
Anti-albumin 
Anthx-1-acid glycoprotein 
Basic drugs 
Propranolol hydrochloride 
Amitriptyline hydrochloride 
Chloropromazine hydrochloride 
!m ipram ine hydrochloride 
Diethylcarbamazine citrate 
Promethazine hydrochloride 
Procainamide hydrochloride 
Phenyl propai10lamine hydrochloride 
Histamine dihydrochloride 
Adrenaline bitartrate 
Piperazine citrate 
Erythromycin 
Hydrochlorothiazide 
Primaquine phosphate 
Chloroquine phosphate 
Alprenolol-D-tartrate 
Steroids 
Progesterone 
Corticosterone 
Cortisone 
Oestradiol 
Acidic drugs 
Warfarin 
Flufenam ic acid 
Source and description 
Dako immunoglobulins Ltd 
Sigma Chemical Company Ltd 
" 
May and Baker Ltd 
Geigy Pharmaceuticals 
Sigma Chemical Company Ltd 
" 
" 
" 
" 
" 
" 
" 
" 
" 
" 
" 
Sigma Chemical Company Ltd 
" 
" 
" 
Sigma Chemical Company Ltd 
" 
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Continued ... 
Material 
Amino acids 
L-tryptophan 
Tyrosine 
Phenylanaline 
Other reagents 
Tris 2-(butoxyethyl) phosphate 
[TBEP] 
Reactive blue 2-sepharose 
CL-6B (Cibacron blue F3G-A 
covalently attached to 
sepharose CL-68) 
Neuraminidase (enzyme from 
clostridium perfringes) 
Source and description 
Sigma Chemical Company Ltd 
" 
" 
Sigma Chemical Company Ltd 
Sigma Chemical Company Ltd 
Sigma Chemical Company Ltd 
All other reagents used were analytical grade. 
AristaR grade of urea was used. 
2.2 Instruments 
\, __ _ 
Perkin-Elmer Model LS-5 Luminescence Spectrometer 
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Model LS-5 Luminescence Spectrometer fitted with a red ") 
sensitive R928 photomultipller was used for quantum yield and corrected 
spectra measuremments. Data were recorded on Perkin-Elmer Mo9e1 3600_ 
data station, with the PECLS li applications software./ The fluorimeter 
,. - -- ------ - ~ " 
gave quantum-corrected excitation spectra through the use of a Rhodamine ·· 
101 quantum-corrected reference. detector. Emission .spectra were 
corrected using a correction graph generated from 250nm to 630nm, as 
described by Williams et al.llO 
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For quantum yield measurements the spectrometer was used as a 
single beam ultraviolet-visible absorption spectrophotometer, essentially 
by placing a mirror at the sample focus to reflect the excitation light into 
the emission monochromator.110 
Perkin-Elmer Model MPF44B Fluorescence Spectrometer 
The spectrometer was fitted with a DCSU-2 corrected spectrum 
unit for corrected and derivative spectra measurements. A thermostated 
sample compartment on the instrument allowed constant temperature 
fluorescence measurements to be carried out. This fluorimeter was used 
for binding titrations and other measurements. 
·- ( ' , 
., 
\ ( V' 
: \ \;' .. --'(_ -'-·(' ;,.l_ , .. , ;::_,·:· 
PyeUnicam SPS-100 Ultraviolet-Visible Spectrophotometer 
This spectrophotometer was used for absorbance measurements 
within the range of 0.1-1.0 absorbance -IHiits and complete absorption 
spectra were scanned for most measurements. 
Baird-A to mic Model SFRlOO Recording spectrofluorimeter . 
The fluorimeter was adapted for phosphorescence measurements 
by incorporating a rotating cylinder, phosphoroscope. The sample 
compartment was also adapted to house a Dewar flask for liquid nitrogen 
measurements. Data were recorded on an Apple Il microcomputer on 
which corrected phosphorescence spectra were generated. The correction 
factors for excitation and emission spectra were stored on the 
microcomputer. All luminescence measurements at 77K were carried 
out on this instrument. 
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Perkin-Elmer Model1000 Fluorimeter 
This filter fluorimeter was used for all flow Injection analysis 
measurements. The fluorimeter was fitted with a flow cell especially 
made of silica tubing. 
LKB Multiphor System 
LKB isoelectrofocusing kit and apparatus (LKB 2117-301 
Multiphor System) were used for measurements of isoelectric points. 
Prepared ampholine PAGA plates were obtained from LKB Ltd. The 
powered pack was obtained from Camlab. A surface electrode from 
Russell pH Ltd. was used for pH measurements on the PAGA plates. 
2.3 Sample Treatment and Preparations 
2.3.1 Preparation of Albumin-Free Protein Samples 
Whole serum, serum fractions and isolated serum proteins were 
freed of albumin by affinity chromatography using Cibacron Blue-
Sepharose Column1ll,l12 as described below. 
The gel was swollen in distilled water for 15 minutes and washed 
on a sintered glass filter several times. Two grams of the gel was required 
for seven millilitres of the column, which could be used several times. The 
column was packed and washed with the starting buffer (phosphate 0.05M, 
pH 7.4) and the expected capacity of the column for albumin was about 
0.28g of albumin. Elution of samples was carried out with the phosphate 
buffer. All albumin was expected to be retained on the column. The 
column was regenerated for further use by stripping the albumin with 0.2M 
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a.\:.. 
N aSCN)_ pH 8. Occasionally the column was washed with 5M - guanidine 
hydrochloride followed by 0.05M tris/HCL/0.05M - NaCl, pH 8.0 to remove 
traces of lipoproteins, which precipitated at the top of the column bed.111 
Pure albumin solution was regularly passed through the column to check for 
its albumin binding capacity. 
2.3.2 Preparation of Modified Alpha-1-acid Glycoprotein Samples 
2.3.2.1 Urea treatment 
ihe alpha-1-acid glycoprotein was treated with various concentr-
ations of urea (OM., lM., 2M., 4M., 6M., 8M., 10M.). The 01:1 AAGP was 
dissolved in the urea solution and left at room temperature for four hours. 
In a second experiment the tt1AAGP was similarly treated with 
10M urea after which the urea was removed by dialysis against distilled 
water at 4 °C. 
2.3.2.2 Reduction and alkvlation 
Reduction and alkylation of the alpha-1-acid glycoprotein, to 
dissociate the disulphide bridge, was carried out as described by Krotoski 
and Weimer.113 The protein was dissolved and dialysed in O.lOM 
mercaptoethenol, HSCH2CH20H for twenty-four hours. The reduced 
mixture was immediately dialysed in the alkylating agent (0.02M 
iodoacetamide ICH2CONH2) for twenty hours at 4°C. The protein sample 
was then freed of the reagents by dialysis against running tap water and 
several changes of distilled water at 4 °C for forty-eight hours. 
In a second experiment, the above reduction and alkylation was 
carried out in SM urea. 0.10M HSCH 2CH20H and 0.02M ICH2CONH2 
dissolved in 8M urea were used as the reducing and alkylating agent 
-------------------------------------------------------------------------------
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respectively. As a control, the protein was similarly treated in 8M urea 
alone. 
2.3.2.3 Removal of sialic acid 
The sialic acid of the (J{l acid glycoprotein was cleaved enzymat-
ically using the enzyme neuraminidase of the organism clostridium 
perfringes as described by Popenoe and Dre0.114 The (J{l AAGP was 
incubated with the enzyme in acetate buffer (O.lM pH 4.8) at 37°C for 8 
hours (6mg of protein per 17 units of the enzyme). Dialysis, to remove the 
freed sialic acid from the mixture, was carried out against distilled water 
throughout the incubation period. As control experiments, the protein 
solution alone and also the enzyme solution were each treated in a similar 
way as described above. 
The sialic acid contents of the enzyme treated (){1AAGP 
compared to that of the native protein were determined by the method of 
Warren.115 The modified, and the native (){1AAGP, were subjected to 
isoelectrofocusing to determine their isoelectric points, and the extent of 
the desialation. 
In the Warren test, the (){1AAGP gave a deep red solution with 
high absorbance at 549nm while no colour was formed with the enzyme 
treated (){1AAGP. The isoelectric point measurements gave pH 2.54 and 
4.98 as isoelectric points for the native and the enz,-me treated <X1AAGP 
respectively. The above results thus confirmed that the sialic acid had 
actually been removed from the enzyme treated protein and this protein 
was used as the asialo (){1AAGP sample in the subsequent chapters. 
Chapter 3 
LUMINESCENCE PROPERTIES OF ALPHA-1-ACID 
GLYCOPROTmN AND BASIC DRUG BINDING 
3.1 Introduction 
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The luminescence of proteins has come to be seen as 
corresponding to the summed contribution of the amino acids (phenyl-
alanine, tyrosine and tryptophan} perturbed by incorporation into a 
polypeptide and by the influence of secondary and tertiary structure of the 
proteins. The commonly determined luminescence properties of the amino 
acids are listed in Table 3.1. The role of each type of the amino acid in 
many different proteins has been extensively studied and reported.116,ll? 
Different proteins with different or similar amino acid compositions 
showed widely differing fluorescence yield values as a result of 
incorporation into the protein structure. As such, the fluorescence and 
phosphorescence of each protein is considered as an intrinsic property of 
the protein itself. 
Table 3.1 AbsorQtion and luminescence QrOQerties of 
aromatic amino acids 
Amino Absorption Fluorescence Phoshorescence Phosphorescence 
acid wavelength wavelength wavelength decay time maxima (nm} maxima (nm} maxima(nm) (sec) 
Tryptophan 220, 280* 348 406,435,456 6.5 
Tyrosine 222, 275* 303 387 2.0 
Phenylanaline 205, 258* 282 385 5.5 
* Absorption wavelength used for fluorescence excitation 
----------------------------------------
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For the convenience of interpretation, the proteins are grouped 
into two fluorimetric classes; Class A proteins, which lack tryptophan but 
possess tyrosine, display luminescence due to incorporated tyrosine 
s 
residues in the protein; Class B proteins, where oc1AAGP belon~ possess 
tryptophan as well as tyrosine and phenylalanine; the luminescence is 
predominantly due to the tryptophanyl residues. Tyrosine contribution in 
class B proteins is very small, and that has been attributed partly to energy 
transfer from the tyrosinyl to the tryptophanyl residues. The fluorescence 
of phenylalanine in proteins is very weak and virtually absent in the class B 
proteins. 
The luminescence of a protein is often sensitive to changes in the 
environment of the macromolecule such as solvent polarity, viscosity and 
pH. When a small molecule binds to a protein the fluorescence property of 
the protein may also alter. The change incurred is usually the quenching of 
the protein fluorescence, or a change in the fluorescence property of the 
small molecule, as discussed in Chapter 1. 
This chapter reports on the luminescence properties of the 
oc 1 AA GP and the effect of basic drug binding on the intrinsic fluorescence 
of the protein or the effect on the fluorescence of the drug itself. It also 
serves as a preliminary investigation for a fluorescent probe for oc1AAGP 
and basic drug binding. The drugs studied are those in common use and 
easily obtainable. Imipramine, propanolol and chlorpromazine are the 
drugs investigated, the structures of which are given in Table 5.1. The 
drugs have a moderate binding affinity for oc1AAGP. 
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3.2 Experimental 
Instruments and materials including sample preparations and 
pretreatments were as described in Chapter 2. Unless otherwise stated, all 
measurements were in 0.05M phosphate buffer pH 7.4 at room temperature 
in a lcm silica cell. 
3.2.1 Corrected Spectra 
Corrected spectra were obtained from the spectrometers as 
described in Chapter 2. 
3.2.2 Determination of Fluorescence Quantum Yield 
The quantum yield of the oc1AAGP was determined relative to 
that of the free tryptophan under the same conditions at 278nm excitation 
wavelength as follows: 
(16) 
Q - quantum yield 
F - -total quanta emitted 
A - qbsorbance of the solution 
I - relative intensity of the exciting light 
N - refractive index of the solution 
subscript pis for the oc1AAGP and T is for the tryptophan. 
Under the conditions of the measurements (absorbance of 
solutions less than 0.05 lffiits) I and N for oc1AAGP and tryptophan solutions 
were assumed identical. Therefore 
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(17) 
Hence, the relative quantum yield was calculated from the ratios of the 
total quanta emitted (areas under the corrected spectra) and the 
absorbance of the tryptophan and oc1AAGP solutions at 278nm. The 
calculated quantum yield of the oc1AAGP was expressed as the percentage 
of the tryptophan quantum yield. 
3.2.3 Determination of Tyrosine Contribution 
The tyrosine contribution to the fluorescence of the oc1AAGP was 
determined as follows: 
(1) A corrected emission spectrum of the oc1 AAG P was 
obtained at excitation wavelength 278nm. 
(2) A corrected emission spectrum of the oc1AAGP was also 
obtained at excitation wavelength 295nm. At this 
wavelength the absorbance due to tyrosinyl residues is 
negligible or absent.117 
(3) The emission spectrum obtained at (2), which is obvously 
lower in intensity than that at (1), is normalised to the same 
height as (1) at 370nm by expansion. At 370nm the 
tyrosinyl emission is considered negligible.117 
(4) The normalised spectrum at (3) was subtracted from the 
spectrum obtained at (1) and the difference was taken as the 
tyrosine contribution to the total fluorescence emission of 
the oc1AAGP at excitation wavelength 278nm. This 
contribution was expressed as a percentage of the total 
oc1AAGP emission. 
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3.2.4 Determination of Energy Transfer 
The measurements and calculations of the extent of energy 
transfer from the tyrosine to the tryptophan residues were carried out as 
described and explained by Steiner for polypeptides, 117 as follows: 
~ obs 
Tryp 
~ obs 
Tryp 
'¥295 
Tryp 
Pr 
f and 
Tryp 
e 
~ 295 
= Tryp 
(;Pr + 
\ Tryp 
PrJ ef 
Tyr 
- is the quantum yield of oc1 AAGP due to the 
tryptophanyl residues at different excitation wave-
lengths (260nm-300nm). The quantum yield was 
determined as above; 
- is the quantum yield of the oc1AAGP at 295nm 
excitation wavelength which is considered to be due 
to the tryptophanyl residues only; 
Pr ll·"· 
f - are the fractionalAabsorptions of tryptophan and 
Tyr 
tyrosine respectively, in the oc1AAGP. These were 
obtained from standard absorption curves of the 
monomers (tyrosine and tryptophan), and the known 
composition of the amino acids in the oc1AAGP 
polymer; 
- is the extent of energy transfer from the tyrosinyl 
to the tryptophanyl residues of the oc1AAGP with 
a value between 0 and 1. 
-----------------------------
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~obs I 
l.rrypt 
1295 
'.trrypt 
was plotted against the excitation wavelength. 
Similarly frPr + e /r \ was plotted against the excitation wave-
\-Tryp Tyr} 
length for various values of e from 0 to 1. The value of e that gave the 
best fit between the former and the latter plots was taken as the extent of 
energy transfer from the tyrosinyl residues to the tryptophan residues in 
3.2.5 Phosphorescence Measurements 
All phosphorescence measurements were carried out in a silica 
tube, 1.5mm bore diameter, immersed in liquid nitrogen (77°K) in the 
Dewar flask, as described in Chapter 2. The alpha-1-acid glycoprotein and 
tryptophan samples were each dissolved in a 50:50 mixture of propylene 
glycol and water. Luminescence spectra of the oc1AAGP and tryptophan 
were recorded· at excitation wavelength 278nm. The phosphoroscope was 
removed for the measurement of total luminescence of the samples. 
~~ 
/\ 't'ate of decay of phosphorescence was monitored at 436nm 
phosphorescence maximum as a plot of intensity against time. A plot of 
the natural logarithm of the intensity versus the time in seconds served as 
a test of first order exponential decay. The average decay time was 
obtained from the slope of the semilogarithm graph. 
3.2.6 Other Measurements 
Other measurements carried out included synchronous spectra, 
and the variation of fluorescence yield of oc1AAGP with pH, urea 
denaturation and concentration of phosphate ions. The effects of other 
-- ---- - ----------
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treatments (described in Chapter 2) on the oc:1AAGP, on its fluorescence 
properties, were also investigated. 
3.2. 7 The Effect of Drug Binding 
The solution of oc:1AAGP in the phosphate buffer was titrated 
with the drug solution in the same buffer. The excitation and emission 
spectra of the oc:1 AAGP and the drug were each investigated for any 
changes in the wavelength and/or intensity of fluorescence as compared to 
pure solutions of the drug and the protein. Drugs investigated were 
chlorpromazine v\ex 320nm, Aem 460nm), imipramine <Aex 280nm,t\em 
400nm) and propranolol (A ex 290nm, Aem 335nm). Aex stands for maximum 
excitation wavelength, and Aem maximum emission wavelength. Absorb-
ances of the oc:1AAGP and drug solutions investigated were well below 0.1 
-ttftits. 
3.3 Results and Discussions 
3.3.1 Fluorescence Spectra 
The corrected excitation, emission and the synchronous spectra of 
oc:1 AAGP and also tryptophan are shown in Figs 3.1-3.5. The estimated 
wavelength.. maxima, quantum yield and tyrosine contribution are all given 
in Table 3.2. Relative to the tryptophan, the emission maximum of 
oc:1 AAGP is shifted about 18nm towards the shorter wavelength. This blue 
shift in emission spectrum is often observed in proteins. The shift has been 
mainly associated with the altered environment of the tryptophan residues 
in the protein compared to aqueous solution of the tryptophan. A 
wavelength shift of as much as 20nm has been reported for some proteins.111 
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Figure 3.1 Corrected fluorescence emission spectra. Excitation 
wavelength, 278nm; Bandwidths, 20nm for excitation and 
lOnm for emission; a - oc1AAGP; t - tryptophan 
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Figure 3.2 Corrected fluorescence excitation spectra. Emission 
wavelengths, 330nm for oc1 AAGP and 345nm for tryptophan; 
Bandwidths, lOnm for excitation and 16nm for emission; 
a - oc1AAGP; t - tryptophan 
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Figure 3.3 Synchronous spectra of <X1AAGP. Bandwidths, 5nm 
for excitation and emission; (a) -.6A10nm; (b) -b.A 70nm 
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Figure 3.5 Synchronous spectra of tyrosine. Bandwidths, 5nm 
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Table 3.2 Fluorescence properties of oc1AAGP at 300°K 
compared to that of tryptophan 
Tryptophan oc1AAGP Fluorescence property in aqueous in aqueous 
Excitation maximum 278nm 278nm 
Emission maximum 348nm 330nm 
Relative quantum yield 1 0.63 
Relative tyrosine 7%, 10% 
contribution 
Extent of energy 0.45 + 0.05 transfer, e • 
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The relative quantum yield was found to be 63% at excitation 
wavelength 278nm. Despite the high tyrosine to tryptophan ratio (12:4) in 
cc1AAGP, the tyrosine contribution to the total fluorescence is very low. 
A value of 7-10% of the total emission at excitation wavelength 278nm 
was found in this work. The presence of tyrosine contribution to the 
fluorescence was further revealed by the synchronous spectra shown in Figs 
3-5. The tyrosine fluorescence in tryptophan containing proteins is usually 
low and the reasons have been reported by several authors>as discussed by 
Steiner\17 which is partly due to tyrosine-tryptophan excitation energy 
transfer. In this work, the extent of transfer, e, from the tyrosinyl to the 
tryptophanyl residues in cc1 AAGP was found to be 0.45 :_ 0.05, which is 
almost half the total excitation energy, or energy absorbed by the tyrosinyl 
residues (Fig. 3.6). On the whole, ground state interactions between the 
aromatic amino acids and the protein environment also occur, which 
together with possible interactions in the excited singlet state, is often 
expected to reduce the quantum yields shown by the tryptophan and 
tyrosine residues in proteins.118 
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3.3.2 The Effect of Environmental Factors on 
the Fluorescence of oc1AAGP 
3.3.2.1 The effect of phosphate ions 
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The fluorescence emission of oc1AAGP decreased with the 
increase in the concentration of phosphate ions, as given in Table 3.3. 
---------------------------------------------------------------------·-----· -
Table 3.3 Effect of phosphate concentration on the 
fluorescence of oc1AAGP 
Concentration Fluorescence 
of emission 
phosphate maximum 
Molar 
0.00 330nm 
0.01 330nm 
0.05 330nm 
0.10 330nm 
0.25 330nm 
0.50 330nm 
1.00 330nm 
2.50 330nm 
5.00 330nm 
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Emission 
intensity 
4.8 
4.8 
4.8 
4.6 
4.5 
3.9 
3.1 
1.6 
0.3 
Phosphate ions have been shown, by some workers, to quench tyrosine, but 
not tryptophan, fluorescence. So much is true of N-acetyl-DL-tyrosine 
methyl amide, but not the tryptophan derivative.119 However, the 
quenching of tyrosine emission does not account for the fluorescence 
quenching observed in this work. The quenching effect may be due to 
strong absorbance usually given by phosphate ions in the ultraviolet region, 
at about 200nm, which overlaps the excitation wavelength region of the 
protein. At lower wavelengths the effect of phosphate ions is even more 
appreciable, which explains the low excitation peaks observed at 220nm in 
the tryptophan and oc1 AAGP excitation spectra, Fig. 3.2. The 
fluorescence excitation peak of tryptophan at 220nm is normally six times 
greater than the peak at 278nm. At 0.05M phosphate concentration, as 
used in the buffer, this pseudo-quenching effect at 278nm wavelength is 
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negligible, hence no significant reduction in the relative emission intensity 
was observed, as shown in Table 3.3. 
3.3.2.2 The effect of pH 
The effect of pH on the fluorescence quantum yield is shown in 
Figs 3. 7 and 3.8. Maximum fluorescence emission was observed at a pH 
value slightly higher than the isoelectric point of the protein. A dramatic 
increase occurred below pH 2 and above pH 12. 
The tyrosine contribution, which is revealed and monitored by 
synchronous spectra, remained constant through the pH region 2-10. The 
ionization of the tyrosine phenol group to form the tyrosinate ion begins at 
about pH 10.120 The loss in the tyrosine fluorescence at a pH greater than 
10 may therefore be due to the tyrosinate formed, the fluorescence of 
which is very low and different <Aexc275nm, Aem348nm) from the neutral 
tyrosine residue. 
The fluorescence due to the tryptophanyl residues also dropped at 
pH greater than 10. According to some authors,120 excitation energy 
transfer does occur from tryptophan to the weakly fluorescent tyrosinate. 
Other pH dependent interactions include the ionization states of the amino, 
carboxylic and imino groups of the amino acid residues of the protein.181 
Ionization of carboxylic groups in oc1AAGP occurs in the pH region of 
maximum bound protons, to pH 5 which is probably responsible for the high 
fluorescence intensity displayed in this region. The ionization of the sialic 
acid, which may or may not affect the protein fluorescence takes place in 
this pH region also. Above pH 5, the ionization of the 9 imidazole groups 
(pKa 6.6) in oc1AAGP occurs, and this may account for the gradual decline 
in the fluorescence intensity between pH 5 and 9. 
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The big decrease in fluorescence observed at pH 2, and below, 
could be due to irreversible conformational changes that occur in this 
region in <X1AAGP. Fluorescence changes at a pH greater than 12 may be 
a result of denaturation or excited state protolysis, which affects 
fluorescence and is also known to occur at a pH greater than 12.117•122 
3.3.3 The Effect of Urea Denaturation on the 
Fluorescence of 01:1AAGP 
In 10M urea the fluorescence quantum yield of <X1AAGP was 
doubled and the emission maximum shifted progressively from 330nm to 
355nm as the concentration of urea was increased from 0 to 10M, as shown 
in Table 3.4. There is also a shift in the absorption maximum from 280nm 
to 273nm. The tyrosine contribution, monitored by synchronous spectra 
measurements, increased only by a quarter on denaturation. For all the 
urea concentrations, the effect of denaturation, and hence the changes 
that were incurred on fluorescence, were reversed when the urea was 
removed by dialysis. 
Table 3.4 Effect of urea treatment on the fluorescence 
a) Nor mal spectra 
of 01:1AAGP 
<X1AAGP 
Absorbance Emission Emission 
treatment wavelength wavelength intensity 
maximum maximum 
10M urea. 273nm 355nm 39 
SM urea 273nm 350nm 19 
6M urea 274nm 345nm 20 
4M urea 275nm 340nm 19 
2M urea 275nm 330nm 20 
lM urea 280nm 330nm 20 
OM urea 280nm 330nm 18 
1------------
I 
b) Synchronous spectra 
oc1AAGp 
treatment 
OM urea 
10M urea 
lOM urea 
83 
Emission intensity 
AA• 70nm f::J.A , 10nm 
0.9, 3.4 1.2 
1.0, 6.8 1.6 
1.0, 7 .o 1.7 
The effect of the urea on fluorescence, which is a result of 
disruption of secondary, tertiary and higher structural organisations, is 
often encountered with most proteins but to a varying extent. However, 
the reversal of the effect by the removal of urea is not achievable for 
some proteins such as the serum albumin. Urea treatment disrupts the 
unique protein configuration which provides the specific quenching 
environment of the aromatic amino acid residues in proteins. The 
fluorescence of the denatured oc1AAGP <Aem. 355nm) compared very well 
with that of tryptophan in lOM urea (Aem. 356nm) which clearly indicates 
that the lower fluorescence emission maximum, 330nm, of the native 
protein, and the reduced quantum yield, are a result of the microenviron-
ment of the tryptophan, and to some extent the tyrosine residues, in the 
native protein molecule. 
3.3.4 The Effect of Reductive Alkylation on the 
Fluorescence of oc1AAGP 
Dissociation of the disulphide bridge of oc1AAGP by reductive 
alkylation caused an increase of about a C<.ll?-rt.e.r of the total fluorescence, 
as shown in Table 3.5. The fact that no change in emission wavelength 
maximum occurred, suggests no denaturation of the protein to have taken 
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place. The effect of the 10M urea used has been removed by the extensive 
dialysis as shown above {3.3.3). The small increase in fluorescence can 
therefore be attributed to the disulphide quenching which has been broken 
by the reductive alkylation. Although sulphydryl groups, produced as a 
result of reduction, do quench protein fluorescence to a lesser extent than 
the disulphide bridge, the reduction of the disulphide bridge without 
alkylation produced no effect on fluorescence in this work, because 
sulphydryl groups formed and unprotected are easily reoxidised to the 
disulphide specie. 
Table 3.5 Effect of reduction and alkylation on the 
fluorescence properties of oc1 AAGP 
native oc1 AAGP 
oc1AAGP + U 
oc1AAGP + U +M 
oc1AAGP + U +M +I 
oc1AAGP + U +I 
U urea treatment 
Emission 
wavelength 
maximum 
330nm 
330nm 
330nm 
330nm 
330nm 
M mercaptoethanol treatment 
I iodoacetamide 
3.3.5 Luminescence Properties at 77°K 
Emission 
intensity 
132 
133 
136 
172 
140 
The luminescence and phosphorescence spectra are shown in Figs 
3.9 and 3.10. The phosphorescence spectra of oc1 AAGP is no different 
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Figure 3.9 Total luminescence spectra recorded at 77°K. 
Excitation wavelength, 278nm; Bandwidths, lOnm for 
excitation and emission; Solvent, aqueous propylene glycol 
(50:50 by volume); a - cx1 AAG P; t - tryptophan 
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from that of the tryptophan except for a 4nm red shift observed with each 
of the three major maxima. The relative intensities are given in Table 3.6, 
which are only a little different from those of the tryptophan. A slightly 
higher value in intensity at the 410nm cx1AAGP maximum is due to the 
significant contribution of the tyrosine residues at this wavelength. The 
tyrosine contribution, in the phosphorescence spectrum of the cx1 AAGP is 
distinct but small and broad, as shown in Fig. 3.10 at about 350-400nm. 
The fluorescence to phosphorescence peaks ratio of the cx1AAGP is only 
2.5 per cent higher than the tryptophan ratio. The phosphorescence decay 
of cx1AAGP, like the tryptophan, is purely first order as shown in Fig. 3.11. 
At 436nm the phosphorescence due to tyrosine in the oc1AAGP is almost 
negligible. Decay times of 6 seconds, compared to 6.9 seconds for 
tryptophan, were obtained. 
Table 3.6 Luminescence properties of cx1 AAGP at 77 °K 
compared to that of tryptophan 
Luminescence Tryptophan in cx1AAGP in 
property propyleneglycol/aqueous propyleneglycol/ aqueous 50: 50 50 : 50 
Fluorescence maximum 319nm 329nm 
Phosphorescence maxima 405nm, 432nm*, 455nm 410nm, 436nm*, 457nm 
Relative intensities of 1 : 1.8 : 1.4 1 : 1. 7 : 1.3 the phosphorescence 
maxima 
Fluorescence to 1 : 3.9 1 : 3.8 phosphorescence ratio 
Phosphorescence 6.9 secs 6.0 secs decay time 
5 10 15 20 25 
TIME (SI 
Figure 3.11 Phosphorescence decay curve at 77°K. Wavelengths, 
278nm excitation and 436nm emission; Bandwidths, lOnm for 
excitation and emission; 
ooo cx1 AAGP; 
xxx tryptophan; 
ln[l] Natural logarithm of phosphorescence intensity 
3.3.6 The Effect of Basic Drug Binding 
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For propranolol and i~ipramine, no fluorescence change (intensity 
or wavelength maxima) was observed in either the protein, or the drug, as a 
result of binding. When cc1 AAGP was titrated by chlorpromazine, there 
was quenching of the protein fluorescence, but no change in the intrinsic 
I 
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fluorescence of the chlorpromazine was observed. The quenching curve 
obtained by the chlorpromazine titration of oc1AAGP is shown in Fig. 3.12, 
and the Scatchard plot, as described in Chapter 1, is shown in Fig. 3.13, 
The binding constant, Ka' was found to be 3.75 x 105M-1 and only one 
strong binding site was identified. 
The quenching of protein fluorescence by the binding of a ligand 
can occur as a result of energy transfer from the excited state tryptophan 
residues to the bound ligand. The general prerequisite for this to occur is 
that the emission band of the donor molecule overlaps the absorption band 
of the acceptor molecule, which is satisfied by the chlorpromazine-
oc1AAGP system. The transferred energy is, however, lost by a non-
radiative mechanism as no effect on the chlorpromazine emission was 
observed. In. this work the possible effect of pseudoquenching by 
fluorescence reabsorption and inner filter effects were eliminated by using 
very dilute solutions of the protein and the chlorpromazine (0.1 absorbance 
iffii.t was maximum). Most of the quenching was observed with a 
chlorpromazine absorbance of less than 0.05 units. Not investigated are 
other specific quenching of the protein fluorescence by the chlorprom-
azine, for example the presence of a chlorine group, which are possible. 
Despite the problems with inherent protein fluorescence, as 
discussed in Chapter 1, and the different mechanism possible for the 
quenching effect, the measure of the binding by this quenching 
measurement appears precise, and the binding parameters obtained agree 
well with the value reported in the literature (Ka = 2.94 x ro 5M-1) *7 
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Chapter 4 
FLUORESCENT LABELS AS PROBES FOR ALPHA-1-ACID 
GLYCOPROTEIN AND BASIC DRUG BINDING 
4.1 Introduction 
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This chapter describes the preliminary investigations which were 
performed to find a suitable fluorescent probe for alpha-1-acid 
glycoprotein from the commonly available basic fluorescent labels. The 
application of the suitable label as a probe for alpha-1-acid glycoprotein 
and basic drug binding is also described. 
Labels studied for fluorescence changes when added to cx1 AAGP 
0. 
are the dansyl derivative of,(basic amino acid (dansyl lysine J\exc. 350nm 
andAem. 580nm) and dansyl cadaverine <Aexc. 350nm, Aem, 580nm). The 
wavelengths given are those in aqueous buffer. Also tried are the high 
affinity fluorescent ~-adrenergic blockers recently synthesised by Atlas 
et al.l 23 These are dansyl analogues of propranolol, DAPN <Aexc. 330nm, 
Aem. 555nm), and 9-aminoacridyl propranolol, 9-AAP <A.exc. 385nm, 
I 445nm), whose structures are shown in Table 4.1. The quantum yield /\em. 
of dansyl derivatives usually increases as the polarity of solvent is 
decreased, while acidinyl derivatives show decreased fluorescence quantum 
yield as the polarity of the medium decreases.124 Such polarity effects 
are often exhibited when the labels bind to proteins as a result of the 
hydrophobic nature of the protein binding site compared to the aqueous 
solvent environment. 
In this work the labels have been tried for suitable changes in 
fluorescence, when bound to oc1AAGP, hence their applicability as probes 
for oc 1AAGP. DAPN, which was found to exhibit large increases in 
Table 4.1 Basic fluorescent labels 
?H 
OCHzCH-CHzNH CH2 CH2 NH-S02 
DAPN /\ 
CH 3 CH3 
CH3 OCH2 CH (OH)CH2 CH2 NH CHz tH--NH 
9-AAP N~ 
Dansyl cadaverine 
Dansyl Lysine 
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fluorescence intensity, when bound to oc1AAGP, has been used as a probe 
for oc1AAGP and basic drug binding. 
4.2 Experimental 
4.2.1 Materials 
9-AAP, DAPN, oc1AAGP, oc1antitrypsin, whole human serum, 
serum fractions, propranolol, dansyl lysine and dansyl cadavarine were 
obtained as described in Chapter 2. 
4.2.2 Method and Sample Preparations 
DAPN: 
9-AAP: 
Modified samples were prepared as in Chapter 2. These 
include removal of sialic acid, reductive alkylation and urea 
denaturation. Albumin-free solutions of serum samples 
were also prepared as described in Chapter 2. Unless 
otherwise stated, all solutions were freshly prepared and 
freed of albumin before use. 
was dissolved in water (40°C) and the pH was adjusted to 
pH 7.4. The solution, which was about lOOpg/ml, was stored 
at 0.05 °C in a dark bottle, and was found to be stable for 
several weeks. Before use, the concentrated solution was 
diluted many fold with 0.05M phosphate buffer, pH 7.4. 
was obtained as 2mg/ml in methanol and it was diluted many 
times with 0.05M phosphate buffer, pH 7 .4, before use. 
Dansyllysine: was directly dissolved in the phosphate buffer before use. 
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Dansyl cadaverine: was also dissolved directly in the phosphate buffer. 
Propranolol: A freshly prepared solution in the buffer was always used. 
4.2.3 Preliminary Measurements 
The fluorescence spectra of each label solution (0.05 absorbance 
.uRH-) was studied. This included an examination of the fluorescence 
excitation and emission spectra of the labels with regard to any changes in 
intensity, or spectral shifts when mixed with ee1AAGP in a 1:1 molar ratio. 
4.2.4 Binding Titrations for ee1AAGP 
Binding titrations were carried out with DAPN only (which 
produced suitable fluorescence changes when mixed with ee1 AAGP). 
Binding measurements were obtained by direct titration, and also 
equilibrium dialysis sometimes, for comparison. 
Direct titration 
The titration was carried out by adding increasing concentrations 
of the DAPN to a single concentration of ee1AAGP. This was achieved by 
putting increasing microliter volumes of DAPN stock solution, and equal 
microliter volumes of ee1AAGP stock solution, into several lOmls-
volumetric flasks. The total Yel11111e of tile flasks were each made up to 
the 101111s mark and shaken thoroughly. Fluorescence measurements were 
carried out immediately at 346nm and 525nm wavelengths of excitation 
and emission respectively. The titration of DAPN was repeated without 
the ee1 AAGP, to obtain the relative intensity at the same wavelengths due 
to the intrinsic fluorescence of the free DAPN, which was non negligible. 
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The binding measurements were recorded as the difference between the 
fluorescence intensity of the DAPN in the protein solution and that in the 
buffer; that is, the fluorescence enhancement effect, against the various 
concentrations of the DAPN added. Several concentrations of oc1AAGP 
(5.5pM, 1.67pM, 1.25pM, 1.17pM, 0.67pM) were studied including 
deasialated (sialic acid removed) oc1 AAGP solutions. 
Equilibrium dialysis 
In this method 5mls of oc1AAGP solutions (O.SSpM) contained in 
several washed visking tubings (molecular weight cut off 1200-1400) were 
dialysed against 20mls of outside solutions containing various quantities of 
DAPN. For each concentration of DAPN, dialysis was carried out in 
duplicates. The dialysis was carried out by shaking in a water bath at 
300°K for 40 hours, which was more than the time required for 
equilibration. The binding measurements were recorded as the difference 
in fluorescence intensities between the inside and outside solutions, against 
the concentrations of the DAPN added. 
4.2.5 Binding Titrations for Serum Samples 
A sample of fresh whole serum was diluted with buffer 
(concentration of the diluted serum oc1 AAGP = 0.017mg/ml) and titrated 
with increasing amounts of DAPN until no further significant change in 
fluorescence enhancement was observed. The maximum enhancement was 
recorded as the total binding of DAPN to the serum sample. The diluted 
serum sample was treated with blue sepharose column, as described in 
Chapter 2, and titrated with DAPN. Pure oc1 AAGP solution (0.017mg/ml), 
all serum fractions, ~-lipoproteins and oc1-antitrypsin were similarly 
-------
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treated, and titrated. The effect of exposure on binding was studied by 
leaving all serum samples and proteins for 30 hours at room temperature, 
before treatment and titrations. 
4.2.6 Binding Titrations for Albumin 
DAPN solution (1.256pM) was titrated with albumin. The same 
concentration of DAPN was similarly titrated with oc1AAGP. For each 
protein the binding measurement was recorded as a change in fluorescence, 
against the titre concentrations of the protein. 
4.2. 7 Binding Titrations for Propranolol 
A solution of DAPN-oc1AAGP complex (1.05pM DAPN + 0.82pM 
oc1AAGP) was titrated with increasing amounts of propranolol, and the 
binding measurement was obtained as the relative fluorescence quenching 
against the concentration of propranolol. Sepharose blue-treated whole 
serum sample, similarly saturated with DAPN, was titrated with the 
propranolol and the quenching produced was monitored. 
4.2.8 The Effect of pH on the DAPN Binding 
Buffers of various pH were prepared from various proportions of 
the buffer salts (Na2HPO 4 and NaH2PO 4). Very low and high pH buffers 
were prepared by adjusting NaH 2Po4 solution with hydrochloric acid, and 
Na2HP04 with sodium hydroxide respectively. The concentration of 
phosphate ions was maintained at 0.05M in all the buffers. The binding of 
2.25J!M oc1AAGP plus 6.61JM DAPN was studied, and the behaviour of pure 
DAPN (6.61JM) in the various buffers was also studied. fn each case the 
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fluorescence intensity at wavelengths; 346nm excitation, and 525nm 
emission was recorded against the pH of the buffer. 
4.2.9 The Effect of Urea Treatment of oc1AAGP on DAPN Binding 
The urea treatment of oc1 AAGP was carried out as described in 
Chapter 2. The fluorescence intensity generated when 3.04pM DAPN was 
added to 1.08pM treated oc1AAGP solution, was recorded for every urea 
treatment. The effect of urea on the fluorescence of the DAPN solution 
alone was also monitored and subtracted. 
4.2.10 The Effect of Reductive Alkylation of oc1AAGP 
on DAPN Binding 
The oc1 AAGP was reduced and alkylated as described in Chapter 
2. The effect of each treatment on the DAPN binding was monitored by 
the fluorescence changes observed for a mixture of 3.04pM DAPN and 
l.OSpM treated oc1AAGP solutions. 
4.3 Data Analysis and Presentation 
The titration results are presented as binding curves, which are 
plots of fluorescence changes against concentration of the titrant (DAPN 
or propranolol). All spectra are presented as displayed on the recorder. 
The apparent association constants, Ka' and the numbers of 
binding sites, were determined according to the method of Scatchard as 
F 
explained in Chapter 1. A plot of equation (14), .,..F against F gives a 
'-'L e 
straight line if Ka is constant (identical sites and no interactions). The 
F 
intercept on the d; axis (condition Fe = O) gives KaF:. The intercept on 
L 
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the Fe axis 
F 
(condition ce 
L 
= 0) gives F: which is the fluorescence 
enhancement due to the total concentration of binding sites, cJ3; from 
which the number of binding sites per protein molecule can be calculated. 
When curvature occurred, as deviations from the normal 
Scatchard plot, different classes of binding sites were assumed, and the 
curve was analysed according to the methods of Rosenthal and Feldman 
TeJe,.ttd. -\:.c 
,{ex[llaiAed in Chapter 1. 
The above plots from equation (14) are suitable for data obtained 
from equilibrium dialysis, because a concentration of free ligand is 
available. In the direct titration methods, only the total concentration of 
the ligand is known. The concentration of the free ligand needs to be 
deduced from the binding curve. An equation derived from the Scatchard 
equation, as shown below, was also used for the analysis of data obtained 
by direct titration: 
If n = number of binding sites 
cc; = total molar concentration of protein) 
similarly 
and 
if the n binding sites are independent and identical. 
concentration of the added ligand (DAPN). 
If R is the fraction of completely bound protein R 
equation (2) becomes 
= 
CL 
c 0 = total L 
then 
Substitute Re; for CpL 
(Cp- RCP) (Ci,- nRC;) 
therefore 1 = 
"lra 
or 1 1 r:R·"K 
a 
Ci, (ft- 1)- nCP (1 - R) 
Fe 
R is also = Fo as obtainable from fluorescence measurements. 
e 
100 
(18) 
eo 
A plot of h versus-; gives a straight line if Ka is constant. Ka is the 
eo 
association constant. The intercept at the If axis is = nCP. Cp is 
known, therefore n is evaluated. 
4.4 Results and Discussions 
4.4.1 Fluorescence Properties of the Labels and their 
cx1AAGP Complexes 
In buffer solution DAPN showed S~e.)''-'-y~Co..\'\1:. fluorescence. It 
fluoresces with an excitation and emission maxima at 330nm and 555nm 
respectively (Figs 4.1, 4.2). On binding to the cx1AAGP, the excitation 
maximum shifted to 346nm, and the emission to 525nm. The most 
pronounced and important effect was the fluorescence intensity which was 
increased about ten times as shown in Fig. 4.3. The change was instant and 
complete on mixing the DAPN and cx1AAGP solutions, and remained 
constant for several hours at room temperature and for several weeks at 
0-5 °C. This suggested that a very stable complex had been formed. Other 
labels investigated, dansyl lysine and dansyl cadavarine, showed no 
fluorescence change when mixed with the cx1 AAGP solution. 9-AAP 
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Figure 4.1 Fluorescence excitation spectra. Emission wave-
length, 525nm; (a) Free DAPN, 3.2pM; (b) DAPN-
ac1AAGP complex, 0.3pM ac1AAGP + l.OpM DAPN. 
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Figure 4.2 Fluorescence emission spectra showing spectral shift 
when DAPN binds to oc1 AAGP. Excitation wavelength, 
346nm; (a) Free DAPN, 5.8J.1M; (b) DAPN- oc1AAGP 
complex, 0.2pM oc1AAGP + 0.60pM DAPN. 
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Figure 4.3 Fluorescence emission spectra showing .enhancement 
effect when DAPN binds to oc1 AAGP. Excitation wave-
length, 346nm; (a) Free DAPN, 10.3!1M; (b) DAPN-
oc1AAGP complex, 2.011M oc1AAGP + 10.3!1M DAPN. 
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showed a decrease of less than 10% of its emission intensity in aqueous 
buffer when mixed with the oc1AAGP in a one to one molar ratio. The 
wavelengths remained virtually unchanged. 
The change in fluorescence properties observed with polarity 
labels, when bound to a protein, is a function of the hydrophobicity of the 
protein binding site, the relative affinity of the label molecule for the 
protein site and the accessibility of the fluorescent moiety of the label to 
the hydrophobic region of the protein. The relative affinity, in turn, is 
dependent on the hydrophobic character of the label itself, which is 
necessary for the hydrophobic types of interaction, as well as other 
functional groups, acidic or basic, responsible for the binding. Dansyl 
lysine and dansyl cadavarine are relatively small, polar and weakly basic 
primary amine derivatives, thus possibly have very low affinity for 
oc1AAGP. Despite the fact that 9-AAP is similar to DAPN, no significant 
change was obtained which is readily attributable to the acridine part of 
the 9-AAP molecule which is probably not accessible to the protein 
hydrophobic site. As reported earlier by Atlas et al.,123 only a small 
a 
change in fluorescence was observed when 9-AAP binds toA~-adrenergic 
receptor site. On the whole, for many labels, the effect of other factors 
such as hydrogen bonding with proton donating solvents, pH, etc., do occur 
as well as polarity effects. 
4.4.2 Binding Parameters for oc1AAGP-DAPN System 
The binding curves are presented as the fluorescence enhance-
ment effect versus the concentration of DAPN, the enhancement effect 
being the difference between the fluorescence intensity of the DAPN in 
the oc1AAGP solution and that in the pure buffer solution. Samples of the 
105 
binding curves are shown in Figs 4.4 and 4.5. Samples of the plots of the 
binding data as described in Section 4.3 are shown in Figs 4.6, 4. 7, 4.8, and 
the values are presented in Table 4.2. At all protein concentrations 
studied, DAPN displayed one strong binding site on oc1AAGP, the binding 
affinity constant being 2 to 3 x 106M-1 depending on the concentration of 
the oc1AAGP. The apparent association constant increased with a 
decrease in the concentration of the oc1AAGP. At low concentrations of 
the protein (0.67pM) two other weaker binding sites appeared as shown in 
Fig. 4.8. and Table 4.2. The presence of the weaker binding sites is visible 
in most of the plots of the binding measurements. The results obtained by 
equilibrium dialysis are similar to those from the direct titration method 
(Table 4.2). 
Table 4.2 DAPN-oc1AAGP binding parameters 
pM 
5.50 
1.67 
1.17 
1.25 
0.67 
0.88* 
asialo oc1AAGP 
Association constant, Ka 
Scatchard Other 
M-1 M-I 
2200000 2240000 
2260000 2300000 
2220000 
3050000 
2700000 3000000 
(60000) 
2110000 
0.88pM* 2410000 
Other 
• 
( ) 
Plot of equation (18) 
Equilibrium dialysis 
Secondary binding sites 
Number of binding sites, n 
Scatchard Other 
0.92 0.98 
0.80 0.96 
0.99 
1.10 
1.00 0.80 
(2.30) 
1.18 
1.06 
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Figure 4.4 DAPN-oc1AAGP binding curves. Concentration of 
oc1AAGP titrated; xxx- 5.5pM, ooo- 0.67pM. 
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DAPN -cx1 AAGP binding curve. 
Concentration of cx1AAGP titrated, l.OOpM. 
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The apparent association constant for the DAPN-oc1AAGP system 
is among the highest recorded for drug-protein complexes. The dependence 
of the association constant on the protein concentration is a phenomenon 
reported by several workers, for ligand-albumin binding, The possible 
effects of molecular aggregation of the albumin at higher concentrations 
have been eliminated and so have the effects of other competing ions 
present as contaminants or buffer components.125 An accurate and more 
108 
Figure 4.6 Scatchard plots for DAPN-oc1AAGP bindmg. 
Concentrations of oc1 AAGP, ooo- 1.67J.1M; xxx- 5.50J.1M. 
specific study or this phenomenon is required in order to explain the 
concentration effects. 
4.4.3 DAPN Binding to Albumin 
When DAPN was mixed with human serum albumin, in a one to 
one molar ratio, the fluorescence emission maximum of the DAPN was 
109 
5 
4 
3 
2 
Figure 4.7 Plot of equation (18) for DAPN-oc1AAGP binding. 
Concentration of oc1 AAGP, ooo- 1.67pM; xxx- 5.50pM. 
shifted from 555nm of the free ligand to 500nm accompanied by a three 
times increase in fluorescence intensity. The results of the albumin 
titration; that is, enhancement effect produced, versus albumin concentr-
ation, is shown in Fig. 4.9, compared to oc1AAGP binding measured under 
the same conditions. A binding ratio of the DAPN to albumin, as estimated 
from the binding curve, was about five. However, the binding appeared to 
be more or a non-saturable type. 
2 
1 
0 6 FsL 
Figure 4.8 Scatchard plot for DAPN-Q(1AAGP binding. Concen-
tration of Q(1AAGP, 0.67pM; straight lines are the resolved 
asymtotes of the curve.l04•105 
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From the shift in emission maximum, it can be concluded that the 
albumin binding site is more hydrophobic than the Q(l AAGP site. The 
lower enhancement effect produced with albumin could be explail)ed by !I 
lower affinity of the DAPN for albumin. The results obtained with albumin 
are. not unexpected because albumin is known to bind both anionic and 
cationic drugs including propranolol, the parent drug of DAPN. Also the 
affinity of basic drugs for a~bumin is relatively very low. 
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Figure 4.9 
DAPN 
CONCENTRATION OF PROTEIN mg/ml 
DAPN-protein binding curves. Concentration of 
titrated, 0.38pM. Protein titrated; xxx - oc1AAGP; 
ooo - albumin (RSA). 
4.4.4 DAPN Binding to Whole Serum Samples 
Untreated serum gave a very high fluorescence intensity on 
binding to DAPN, magnitudes higher than that expected from oc1AAGP 
level in the serum. The emission maximum was also shifted from the 
555nm of the free DAPN to 500nm. Such an enormous emission signal in 
the serum is mainly due to albumin which forms about 60% of the total 
112 
serum proteins. In addition the binding to albumin, being non-saturable, 
.contributed. to the high signal, despite the low affinity that DAPN has for 
' ...... ·-· _. .. ," .. "··.' ~~ ~ 
albumin. Other proteins that might bind to DAPN are the lipoproteins 
which are known to bind basic drugs. 
When fresh serum was passed through sepharose blue column, the 
enhancement effect, therefore the binding obtained with the effluent was 
essentially that of oc1AAGP, as shown in Table 4.3. The finding showed 
that all interefering protein(s) have been removed by the sepharose blue 
column. The column is known to selectively bind only albumin, and to a 
certain extent lipoproteins are precipitated at the top of the column. 
However when an old serum (exposed for 30 hours in room conditions) was 
similarly treated, the emission was three times more than expected. Pure 
oc1AAGP solution in buffer exposed in the same way showed no change in 
its binding properties. As such the changed binding in the serum can only 
be attributed to other binding specie(s) whose alteration as a result of the 
exposure causes enhanced DAPN binding. Lipoproteins undergo lipolysis in 
stored serum, which may facilitate their passage through the sepharose 
column. 
4.4.5 DAPN Binding to Serum Fractions 
~-lipoproteins produced a fluorescence enhancement effect on 
DAPN which was not observed when the protein sample was passed through e. 
blue-sepharose column. However, an old {l-lipoprotein solution (exposed 
for thirty hours in room conditions) produced a fluorescence enhancement 
effect on DAPN even after passage through the column. occantitrypsin, 
passed through the column, showed a negligible effect on the DAPN 
" fluorescence. Of the other serum fractions studied, only ex-globulin IV -4 
113 
Table 4.3 Binding: of DAPN to serum sam12Ies 
Concentration of oc1AAGP Relative fluorescence 
Sample pM enhancement effect 
Column No column Column No column 
Fresh 
oc1AAGP 0.425 0.425 2.0 2.1 
solution 
Fresh 
diluted 0.425 0.425 1.9 13.5 
serum 
Old 
oc1AAGP 0.425 0.425 2.0 2.1 
solution 
Old 
diluted 0.425 0.425 6.1 
serum 
~-lipoproteins 
0.05mg/ml 0.00 0.20 
0.035mg/ml 0.10 1.30 
oc1-antitrypsin 
' 0.20 0.70 0.05mg/ml 
oc-globulin 
fraction IV -4 0.25 0.60 
0.052mg/ml 
Column Treatment with blue sepharose column 
showed some enhancement effect and this has not been identified with any 
protein but probably the oc1AAGP itself in the fraction. 
It can be concluded that besides oc1AAGP, only albumin and 
lipoproteins contribute significantly to the DAPN binding in serum. The 
contributions of these two proteins can totally be removed by passing the 
serum sample through supharose column. In fact most serum samples for 
--------- ------
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fluorescence measurements are treated somehow to reduce the significant 
background fluorescence encountered in serum samples. A blue-sepharose 
column seems to be the most favourable and attractive method as of now, 
which makes it nothing more than a routine procedure in serum 
fluorescence analysis. In addition, traces of albumin are common as a 
contaminant in isolated serum proteins, hence blue-sepaharose treatment is 
required for accurate work. All the above make serum oc1AAGP binding 
assay, with regard to DAPN, essentially similar to that of pure oc1AAGP 
solutions. The results obtained with the old (J-lipoprotein sample further 
point : to the effect of lipolysis on the DAPN binding assay in serum. 
4.4.6 Propranolol Binding 
The quenching curve of the propranolol on DAPN-oc1AAGP 
fluorescence is shown in Fig. 4.10. The propranolol quenched the 
fluorescence intensity to that of free DAPN in buffer. DAPN added to 
blue-sepharose treated serum was similarly quenched by propranolol. The 
fluorescence quenching can only be attributed to the displacement of the 
DAPN from its binding site by the parent drug, propranolol. Inner filter 
effects have been eliminated by using propranolol solutions whose 
absorbance is negligible (less than 0.05 absorbance units} at 346nm, 
excitation wavelength. Energy transfer is not expected to occur from the 
DAPN or protein or even the complex, to the propranolol (Aexc. 285nm, 
Aem. 330nm}. Competitive binding between DAPN and propranolol is not 
unexpected since the dansylation of propranolol to form DAPN did not 
involve its protein binding group. In essence DAPN binds in a way similar 
to propranolol, which makes it a good probe for basic drug binding. 
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CONCENTRATION OF PROPRANOLOL 
Figure 4.10 Displacement of DAPN fromoc1AAGP by propranolol. 
O.SOpM oc1 AAGP + 9.0pM DAPN was titrated with propranolol: 
ooo- Asalio oc1AAGP; xxx- Native oc1AAGP 
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4.4. 7 The Effect of Removal of Sialic Acid on DAPN binding 
The binding curve for asialo-oc1AAGP as compared to the native 
oc1 AAGP is shown in Fig. 4.11, and the binding plots parameters are given 
in Fig. 4.12 and Table 4.2. Despite the fact that removal of sialic acid 
caused a change in the isoelectric point of the oc1 AAGP from 2.54 to 4.98, 
no change was observed in its DAPN binding characteristics. The result 
showed that no role is played by the sialic acid group in the DAPN binding, 
hence in basic drug binding. Similar results were obtained with propranolol 
binding displacements (Fig. 4.10). 
4.4.8 The Effect of Urea Denaturation of oc1AAGP 
on DAPN Binding 
As the concentration of urea was increased from 0 to 4M the 
enhancement effect, hence the binding decreased. Above 4M urea 
concentration no enhancement was observed (Table 4.4). Removal of the 
urea by dialysis restored the binding properties of the DAPN. The change 
in the DAPN binding of the oc1 AAGP corresponds very well with the 
denaturation of oc1AAGP revealed by the fluorescence studies of urea-
treated oc1 AAGP in Chapter 3. The results demonstrate the role of 
secondary and tertiary structure of oc1AAGP in its DAPN binding, which 
provides information about the nature of DAPN and basic drug binding sites. 
4.4.9 The Effect of Reductive Alkylation of oc1 AAG P 
on DAPN Binding 
The results of reductive alkylation are given in Table 4.5. 
Reduction alone produced a fifty per cent decrease in enhancement effect 
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Figure 4.11 DAPN-oc1AAGP binding curves. 
xxx- 0.881JM native oc1 AAGP 
ooo- 0.881JM asialo oc1 AAGP 
Figure 4.12 Scatchard Plot DAPN-oc1AAGP binding. 
XXX - native oc1AAGP 
• t 1 . - asialo oc1 A'AGP 
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Table4.4 Effect of urea treatment of oc1AAGP on 
DAPN binding 
Concentration Fluorescence emission 
of 
urea Wavelength max. 
M 
0 525nm 
1 525nm 
2 525nm 
4 525nm 
6 550nm 
8 550nm 
10 550nm 
Concentration of oc1AAGP = l.OOpM 
Concentration of DAPN = 5.10pM 
Enhancement 
3.3 
2.7 
2.7 
1.4 
o.o 
0.0 
0.0 
Table 4.5 Effect of reduction and alkylation of oc1AAGP 
on DAPN binding 
Treatment Fluorescence emission 
of 
oc1AAGP Wavelength max. Enhancement 
Native oc1AAGP 525nm 110.0 
oc1AAGP + U 525nm 108.0 
oc1AAGP + U +M 525nm 66.0 
oc1AAGP + U +M +I 560nm 2.0 
OClAAGP + u +I 525nm 74.0 
U lOM urea 
M Mercaptoethanol treatment 
I lodoacetamide treatment 
119 
Note: All the oc 1AAGP samples were freed of reagents before DAPN 
binding measurements. 
120 
while reduction followed by alkylation eliminated most of the enhancement 
effect. As noted in earlier work, Chapter 3, reduction dissociated the 
disulphide bridge of oc1 AAGP, reduction followed by alkylation being more 
efficient. As discussed in .Chapter 3, dissociation of the disulphide bridge 
caused no change in the secondary and tertiary structures of oc1AAGP, 
revealed by the fluorescence properties. Reductive alkylation therefore 
demonstrates the role of the disulphide bridge of the oc1 AAG P in the 
construction of the DAPN and basic drug binding site. 
4.4.10 The Effect of pH on DAPN Binding to oc 1AAGP 
The fluorescence enhancement produced by the DAPN-oc1AAGP 
increased steadily up to pH 10, above which a drastic decrease was 
observed (Fig. 4.13). At pH 12 there was virtually no enhancement effect. 
The fluorescence emission of the free DAPN in buffer remained almost 
constant for a pH range three to twelve. It can thus be, concluded that the 
stability or the affinity constant of DAPN-oc1AAGP complex increased as 
the pH increased from three to ten, above which, possible alterations in the 
protein conformation inhibited the DAPN binding. lonizations of the 
carboxylic, amino, imino and sialic acid groups of the oc1 AAGP are known 
to take place between pH 5 to 10. There is also the possible effect of 
DAPN ionization with pH. The above effects and informations suggest the 
involvement of protolysis in the DAPN binding and possibly basic drug 
binding to oc1 AAGP. Asialo oc1 AAGP showed similar binding behaviour at 
the various pH values. 
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Figure 4.13 Effect of pH on DAPN binding to oc1AAGP. 
Concentration of DAPN, 1.5pM; xxx- 2.25pM native oc1AAGP; 
ooo- 2.25pM asialo oc1AAGP; ..• -buffer. 
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Chapter 5 
DANSYL ANALOGUE OF PROPRANOLOL (DAPN) 
AS A FLUORESCENT PROBE FOR BASIC 
DRUG BINDING INTERACTIONS 
5.1 Introduction 
122 
Despite the clinical significance of drug interactions, little 
systematic study has been carried out to characterise the binding and to 
evaluate the binding affinities of basic drugs. As a whole, studies of 
protein binding of basic drugs have been inhibited by the lack of a suitable 
fluorescent probe. 
This chapter reports on the use of the fluorescent probe, DAPN, 
developed for oc1AAGP, for the study of basic drug binding interactions. 
Possible interactions of basic drugs with steroids for oc1 AAGP binding site 
was also studied. The study of the inhibition of basic drug binding to 
oc1AAGP by tris(-2-butoxyethyl) phosphate (TBEP), which is a contaminant 
prese~t in blood collected in vacuitainers,42 is also included. Other 
interaction studied is the effect of immuno reaction by oc1 AAGP on basic 
drug binding. 
The basic drugs studied, steroids and TBEP, are given in Tables 
5.1 and 5.2. 
I 
Table 5.1 Structures of some basic drugs 
Structure 
~ (jH~3 N~H~2 
CL-
Name 
Amitriptyline 
Imipramine 
Chlorpromazine 
j CH2 CH=CH2 Alprenolol 
CH2CH(OH)CH2NH CH2CH(OH)CH3 
Propranolol 
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Table 5.1 Cont'd. 
s 
~ 
CHz-y_H:-N ~H~2 
CH3 
fH ~ 
NH2- (CH2)3-CH-N ~ 
CH30 ~ 
1\ 
HN NH 
\_/ 
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Promethazine 
Primaquine 
Procainamide 
Piperazine 
Histamine 
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Table 5.1 Cont'd. 
CH (Of-()CH(NH~ CH3 
Phenyl propanolamine 
Hydrochlororothiazide 
Diethylcarbamazine 
0 
Digoxin 
Table 5.1 Cont'd. 126 
9H3 yH3 ?H HO 
CH-CO•CH-CHz-CH-CH-CH3 . 
I ', I 
HC-OH HC • O CH3 1 . • 
CHa-r- OH . <j:H-CH3 
CHO •CO•CH-CH • 0 CH3 I I 
C2H5 CH3 
Erythromycin 
113S.f' 
0 
0 
H 
Table 5.2 Structure of some steroids 
Structure 
CH3 
0 
Name 
Progesterone 
Corticosterone 
Cortisone 
Oestradiol -17(3 
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5.2 Experimental 
5.2.1 Materials 
DAPN 
<X1AAGP 
Basic drugs 
TBEP (density= 1.006, ref. index, N~0 1.4359) 
Anti-<X1 AAGP 
All materials were obtained and described as in Chapter 2. 
5.2.2 Methods 
5.2.2.1 Preparation of sample 
128 
Solutions of DAPN. <X1 AAGP, and basic drugs were prepared and 
treated as in Chapter 2. 
TBEP solution was prepared as follows: TBEP and the phosphate 
buffer 50:50 by volume was shaken and stirred for 10 minutes. The mixture 
was centrifuged for 10 minutes, to aid separation of the aqueous and the 
TBEP layers. The concentration of TBEP in the aqueous layer was 
determined by absorbance measurements at 202nm, against the buffer. 
Standard TBEP solution was prepared in methanol, and the absorbance 
measured against methanol at 202nm. The absorbance of the standard 
solution was used to calculate the concentration of TBEP in the aqueous 
layer. 
5.2.2.2 Binding measurements 
All binding measurements were carried out in Perkin-Elmer Model 
MPF 44B fluorescence spectrometer as described in Chapter 2. Measure-
129 
ments were made in lcm silica cell at 346nm (excitation) and 525nm 
(emission) and in 0.05M phosphate buffer (pH 7.4). 
Basle drugs and TBEP 
A DAPN-oc1AAGP complex solution was titrated with the 
displacing agent (basic drug or TBEP solutions), and the fluorescence 
quenching was monitored. Free DAPN solution and pure oc1AAGP solution 
were each titrated, with the displacing agent as control experiments. To 
avoid any pseudo quenching and inner filter effects, at no time did the 
absorbance of the added drug or TBEP exceed 0.05 tilffis. Measurements 
were recorded as fluorescence quenching against the concentration of the 
drug or TBEP. 
Steroids 
An oc1 AAGP solution was incubated with, and dialysed in, the 
steroid solution for 40 hours. The steroid-treated 01:1 AAGP solution was 
then titrated with the DAPN. The oc1AAGP solution was treated in a 
similar way, but without the steroid, and was titrated with DAPN for 
comparison. In both cases fluorescence enhancement was measured against 
the concentration of the DAPN. 
Digoxin 
01:1 AAGP was treated with digoxin (insoluble In buffer) in the 
same way as the steroids above, before titration with the DAPN. 
Immunoreaction 
The <X1AAGP was incubated with anti oc1AAGP in various 
proportions for 2 hours and then titrated with DAPN. Anti oc1 AAGP alone 
L_ _________________________________________________ . __ _ 
_ ___j 
----------
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and the oc1AAGP were each treated in a similar way and titrated with the 
DAPN. 
5.3 Data Presentation and Analysis 
Binding displacement curves are presented as fluorescence 
quenching versus the concentration of the displacing agent. Binding data 
were analysed by equation (11), 
r 
R = 
Co K.c 
L 
(11) 
For the fluorescence titration method c0 and CL' which are the 
concentrations of the free drug and free DAPN respectively, are not 
available but 
c0 and Cl, are the total concentrations of the added drug and DAPN 
respectively. CBL and c80 are the DAPN-oc1AAGP and drug-oc1AAGP 
complexes respectively. 
therefore 
also 
r 
R 
r 
R 
r 
= 
= 
ClJ- CBD 
K ..,.c....,t~--,C""'B_L_ 
(Cv!CJ3) - (c80/CB) 
K (CL/Cs) - (CBL/Csl 
= R 
therefore, 
r 
'R = 
K (Ci)!CJ3)- r 
<ctlca>- R 
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(19) 
rand R are obtained from the titration measurements as shown in Chapter 1. 
(C 0 /C 0 )- r 
A I t Of r D B Id . . ht 1' '1f P o 'R versus (Cl/Csl _ R wou giVe a stra1g me 
binding is competitive for sites which are identical and independent. The 
slope, K, is the relative constant (the ratio of the association constant of 
the drug, Kb, to that of the DAPN, Ka). Ka has been determined in a 
separate experiment, as in Chapter 4, hence Kb can be calculated. 
For some drugs studied the inhibition was calculated as 
percentage displacement which is equal to 100r. 
5.4 Results and Discussions 
5.4.1 Basic drug binding displacements 
The general survey of basic drug displacement effects on DAPN is 
given in Table 5.3. All the basic drugs, except digoxin, showed some 
quenching, hence displacement of the DAPN from its binding site. 
Displacement reaction was complete for all drugs within five minutes of 
mixing and measurement. The fraction of fluorescence quenched remained 
constant for over two hours. While some drugs are very effective 
inhibitors of the DAPN binding to oc1AAGP, others are only weak 
inhibitors. 
Tertiary amine derivatives seem to be more powerful than the 
secondary amine derivatives, which are in turn more powerful than the 
primary amines in their inhibitory effects, This finding is in agreement 
with that of Borga. 46 He found that imipramine and amitriptyline bind 
132 
more in plasma than the demethylate forms (desmethyl-imipramine and 
nortriptyline repectively). 
Table 5.3 Displacement of DAPN from oc1AAGP 
by basic drugs 
[oc1AAGP] = 1.00pM 
% DAPN displaced 
Drug 
1.24* 5.62* 22.5* 
Amitriptyline 22 50 80 
Imipramine 19 43 78 
Chlor~romazine 45 72 
Alprenolol 14 38 57 
Propranolol 13 36 50 
Erythromycin 9 35 48 
Promethazine 11 31 43 
Primaquine 19 29 38 
Procainamide 11 19 35 
Piperazine 14 20 27 
Histamine 7 15 22 
Phenylpropanolamine 20 
Hydrochlorothiazide 6 15 19 
Diethylcarbamazine 6 16 
Digoxin 0 0 0 
* Drug:DAPN molar ratio 
Although it is difficult to define a true correlation between the 
structure of the drug and the binding, it is possible to predict which drugs 
belong to the high or low affinity groups. Although the interaction is 
mainly hydrophobic in nature, the basic group on the drug molecule plays 
·~ .. -~ 
an important role. The more basic the group the greater the binding 
affinity, other factors being the size, configuration and probably 
aromaticity of the drug molecule. 
- ------- --------
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For some drugs, complete binding curves were obtained as shown 
in Figs 5.1-5.5. For all the drugs, where complete titration was carried 
out, the fluorescence of the cx1AAGP-DAPN was quenched to the 
fluorescence of the free DAPN, as the concentration of the drug was 
increased. This indicates a complete displacement of DAPN from all its 
binding sites by the drugs. The plots of equation (19) for the drugs are 
shown in Figs 5.6-5.8. Straight lines with excellent correlation 
coefficients were obtained, which showed that the inhibition of the DAPN 
binding by the drug is a eompetitive one, and the slope gave the relative 
constant as explained in section 5.3. The values of the relative constants, 
hence the association constants, of the drugs are presented in Table 5.4. 
For those drugs whose binding affinities have been determined by other 
methods, there. is a good agreement with the values obtained in this work, 
which demonstrates the suitability of this fast and sensitive method for the 
determination of the apparent association constants of basic drugs. 
Table 5.4 Binding affinities of drugs and TBEP from 
DAPN displacement measurements 
[cx1AAGP J = l.OpM., Ka = 3000000 M-l 
Drug 
Amitriptyline 
Imipramine 
Propranolol 
Erythromycin 
Diethylcarbamazine 
TBEP 
Relative 
constant 
K 
0.05700 
0.02200 
0.00880 
0.00670 
0.000023 
0.00471 
Ass!! constant 
of the drug 
Kd 
M-1 
171000 
66000 
26400 
20100 
690 
14100 
Literature 
values 
of Kd 
M-1 
60000 
92000 
30500 
.) 
(tt6J 
(4-GJ 
(Il-l/-) 
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Figure 5.1 
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CONCENTRATION OF AMITRIPTYLINE mM 
Displacement of DAPN from oc1 AAGP by amitriptyline. 
Concentration of oc1AAGP, l.OOpM. 
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CONCENTRATION OF PROPRANOLOL mM 
Displacement or DAPN from oc1AAGP by propranolol. 
Concentration of oc1 AAGP, 1.0011M. 
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CONCENTRATION OF IMIPRAMINE mM 
Figure 5.3 Displacement of DAPN from oc:1AAGP by imipramine. 
Concentration of oc:1AAGP, lOOjiM. lp = fluorescence 
enhancement arbitrary units. 
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CONCENTRATION OF DIETHYLCARBAMAZINE mM 
Displacement of DAPN from oc1AAGP by diethylcarbamazine. 
Concentration of oc1AAGP, l.OOpM. 
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6 
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o~----+-----~----~-----+2L~~~ 1 2 3 4 5 
Figure 5.5 
CONCENTRATION OF ERYTHROMYCIN mM 
Displacement of DAPN from <X1AAGP by erythromycin.· 
Concentration of <X1AAGP, l.OOpM. 
Diethylcarbamazine binds competitively, as shown in Fig. 5.6, but 
the affinity is very low. At very high drug concentrations, which is 
necessary for low affinity drugs, conformational changes in the protein are 
possible. This may explain the emergence of a new correlation at high 
diethylcarbamazine concentration. Deviations are also possible rrom drug 
decomposition on long time exposure, and the involvement of secondary 
binding sites can complicate the analysis or the results. In this work only 
the one strong binding site for the drugs and the DAPN appeared to 
dominate. 
. 
----------------------------------------- -
4 
3 
0 
2 y. 
0 
1 " 0 
Figure 5.6 Plot or equation (19) DAPN and basic drug compet-
itive binding. Concentration of oc1AAGP, l.OOpM; 
xxx- Erythromycin, ooo- Diethylcarbamazine, 
£ and X as in text. 
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No displacement was observed with digoxin, even at high 
concentrations. This drug is distinctly different in its structure, 
particularly the basic moiety, from the other basic drugs. The drug may 
have a totally different binding site on oc1AAGP or the affinity for this 
protein may even be totally lacking. 
Figure 5.7 Plot or equation (19) DAPN and basic drug compet-
itive binding. Concentration of <Xl AAGP, l.OOpM; 
ooo - Propranolol, xxx - TBEP, R and X as in text. 
5.4.2 The Effect or Steroids on DAPN Binding 
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For steroids, no effect was observed on DAPN binding to 
<X1 AAGP. The steroid-treated <X1AAGP behaved in the same way as the 
untreated protein. This shows that steroids, which are known to bind to 
<XI AAGP, do not share a binding site with DAPN and interaction between 
basic drugs and steroids can therefore not be expected to occur. 
4 
0 
0 
80 X 
Figure 5.8 Plot of equation (19) DAPN and basic drug compet-
itive binding. Concentration of cx1AAGP, l.OOpM; 
ooo- Imipramine, xxx- Amitriptyline, 
~ and X as in text. 
5.4.3 The Effects of Immunoreaction of cx1AAGP 
on DAPN Binding 
141 
No quenchmg of DAPN-cx1AAGP fluorescence was observed as a 
result of anti-cx1AAGP and cx1AAGP reactions. As such, the immuno 
reaction does not interfere with DAPN binding on cx1AAGP, and similarly 
with basic drug binding. 
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2 4 6 
CONCENTRATION OF TBEP mM 
Displacement of DAPN from oc1AAGP by TBEP. 
Concentration of oc1 AAGP, l.OO).IM. 
5.4.4 TBEP Binding Displacements 
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The binding curve for TBEP competition in shown in Fig. 5.9. The 
plot of equation (19) gave a straight line (Fig. 5.8), indicating competitive 
inhibition of DAPN binding by TBEP. From the association constant given 
in Table 5.4, TBEP ranks among the efficient inhibitors of DAPN binding. 
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This explains the inhibitory effect of TBEP observed even at very low 
levels, in blood collected in vacuitainers. Trace quantities of this agent 
can interfere immensely with basic drug binding, and may hinder the 
binding of weak basic drugs entirely. 
-----------------~ 
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Chapter 6 
AUTOMATION BY FLOW INJECTION ANALYSIS 
6.1 Introduction 
Despite the enormous literature that exists on automated methods 
of analysis, hardly any automated procedures exist for drug-protein binding 
studies. Continuous ultrafiltration has been applied to study drug binding 
to human serum albumin. A number of dynamic dialysis methods based on 
Fick's law have also been applied to drug-protein binding studies. In both 
methods, as described in Chapter 1, the improvement is in the speed of the 
separation step and convenience, at the expense of sensitivity and 
precision. Large parts of the procedures remained unautomated and 
classical. Homogeneous methods require no separation step, hence are 
more easily automated, a feature which was realised and applied only 
recently by Miller and coworkers.97,126,127 
Since 1975, flow injection-analysis (f.i.a) has gained considerable 
interest as a method of automating various analytical procedures 
conveniently at minimum cost and with great speed. F.i.a may be defined 
as an automated process which involves the insertion of sequential discrete 
sample solutions into an unsegmented continuously flowing liquid stream 
with subsequent detection of the analyte. Abundant literature has 
accumulated on its application and a number of reviews exist which 
described the process.128- 130 Basically, when the sample is first injected, 
it forms a well-defined sample plug in the stream. As the sample moves 
through the channel, which is usually of narrow bore tubing, the plug 
disperses into, and then mixes with, the carrier stream to form a 
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concentration gradient. If the carrier stream is a reagent the dispersion is 
accompanied by a chemical reaction between the sample and the reagent. 
Dispersion has been defined as 
D = = constant. 
Cmax is the concentration of the undispersed sample 
C is the concentration of the dispersed sample zone. 
Hmax and H are the measured peak heights due to undispersed and 
dispersed sample zones respectively. The total dispersion in an f.i.a set up 
is the product of the dispersion in the injection system, flow system and 
the detector. 
0 total = 
The extent to which a sample plug disperses during its passage through a 
narrow tube under conditions of laminar flow has been studied by numerous 
workers and reported. The magnitude of the dispersion is found to be 
dependent on the operating parameters applied to the system, which 
include tubing bore diameter, tubing length, flow rate, sample volume and 
sometimes coil diameter. The dispersion is often considered in terms of 
three general categories; limited, medium and large depending on the 
extent to which the sample disperses. The quantitative definition and 
equation for each of the three categories have been given and explained in 
the literature.129 
In limited dispersion, the sample integrity is maintained to a high 
degree. This is ideal when f.i.a is used just as a sample inlet system such 
as for pH measurements. As minimal a dispersion as possible is allowed for 
maximum sensitivity and high throughput. 
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Medium dispersion has been used for most f.i.a applications. For 
many systems the extent and rate of chemical interaction have to be taken 
into account. A maximum sensitivity is a factor of dispersion and also 
extent of chemical reaction. 
For many systems in which either medium or limited dispersion is 
suitable, large dispersion causes unnecessary dilution of a sample and the 
consequent reduction in sensitivity and throughput. Large dispersion can 
be utilised, however, to give a substantial degree of mixing between the 
injected sample and the carrier stream, hence dilution, which may be 
useful for the analysis of concentrated samples. A well developed 
concentration gradient is also formed as is necessary when performing 
continuous flow titrations and calibrations.131 
Sample dispersion decreases with flow rate. In fact when the flow 
rate is zero dispersion virtually ceases. This concept has been exploited 
for stopped flow procedures when a long reaction time is required.l 32 
Conventional f.i.a 
In its simplest form, conventional f.i.a involves injection of a 
sample into a carrier stream, which may be the reagent, and the detection 
is usually a single point determination in the form of a peak height. To 
minimise consumption of reagent as well as sample, a merging zone 
principle was developed. 133 In this operation both sample, and reagent, 
are injected into a carrier stream and directed to a confluence point. The 
two plugs then meet, mix and are carried through to the detector, 
sometimes via a reaction coil. The merging zone method is most suitable 
when both an expensive sample and reagent are involved. On the whole, 
conventional f.i.a methods appear to be the most applicable, and most work 
reported so far on f.i.a is in fact conventional methods. 
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Gradient f.i.a 
Titrations can also be performed continuously by f.i.a as 
demonstrated by Ruzicka et al.l 28 In this method, a well formed 
concentration gradient produced as a result of large dispersion is directed 
to a junction, where the sample mixes with titrant. Basic models and 
equations for the concentration gradient have been given by some 
workers.134,135 Others have extended its application for gradient dilution 
and calibration purposes.132,13G,l37 
Many different detectors have been used in f.i.a. The suitability 
of fluorimetry as a detection technique has been demonstrated by 
Braithwaite and Miller138 and also Lim et a1.l39 Response is fast, 
and linear in fluorescence detection, which also promotes the f.i.a with the 
added advantage of sensitivity. 
Flow injection analysis with fluorimetric detection has been 
applied by Miller103 and Sturley126 for the studies of a fluorescent probe, 
ANS, and acidic drugs binding to serum albumin. The work was carried out 
totally using the conventional f.i.a procedures. In this project, the 
application of the conventional f.i.a is extended to the studies of basic 
probe, DAPN, and basic drug binding to oc1AAGP. The gradient f.i.a, which 
appears superior for titration measurements is also proposed for the study 
of both the acidic and basic ligands to albumin and oc1 AAGP respectively. 
6.2 Experimental 
6.2.1 Apparatus 
A flow injection analysis set up consists essentially of pressure 
head or pump which propels the carrier stream(s), an injection port for 
----------------------------------------
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reproducible injection of a well defined sample volume into the carrier 
stream, a manifold which holds the flowing streams, and a detector. 
Peristaltic pumps (Gilson Mini HP-4 channel or lsmatec Mini-S 
type) were used and operated with colour-coded pump tubes of suitable 
diameters to obtain the desired flow rate. 
Injection port 
Sample injection was carried out using a Rheodyne valve. While 
the sample is being injected by a syringe into a sample loop the carrier 
stream comes to a standstill. When the valve has been turned, the 
precisely metered amount of sample is inserted by the carrier stream from 
the sample loop into the reaction line. The sample loop which holds the 
sample prior to injection is made from tubing of various lengths. 
Manifolds 
The manifolds were made from polyethylene tubing (0.50-1.02mm 
i.d. For gradient f.i.a, a mixing chamber was sometimes used. Mixing 
chambers of volume (0.4mls-7.0mls) were made of glass or perspex: each 
consisted of a lower cylindrical unit and an upper part with a dome shaped 
inner cavity. A teflon covered magnetic stirring•oar was included for 
effective mixing. For. mixing chamber volumes of less than 0.4mls, a 
length of polyethylene tubing was used instead of a separate vessel. 
Commercially obtained f.i.a apparatus (Bifok, Sollentuna, Sweden) 
was used for merging zone studies. It incorporates a rotary valve that 
dispenses 30-lOOpl with a repeatability of 1%. Two volumetric bores in 
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the rotor allow precisely measured sample and reagent to be introduced 
simultaneously into the carrier stream. The manifold consists of 
polyethylene tubing, plexiglas tubing connectors and a thermostat. 
Dialyser 
For some analyses a dialyser was used. It consisted of two 
plexiglas blocks with a precision semicircular channel cut into their inner 
surfaces. A cellulose dialysis sheet (Mol.wt. cut off 12-14,000) was placed 
between the blocks, the channels of which were aligned on either side of 
the membrane to form a single tube. The channel on one side of the 
membrane formed part of the f.i.a reaction line. Small molecules could 
cross the membrane and be washed out by flowing buffer on the other side. 
Detector 
A Perkin Elmer Model 1000 filter fluorimeter, fitted with a flow 
cell with silica tubing of 1mm i.d. and 45pl volume, was used as a 
detector. Signals were recorded on a Bryan 27000 chart recorder. 
The conventional f.i.a systems for single channel and merging 
zone methods are shown in Figs 6.1 and 6.2, while the gradient f.i.a 
arrangements are shown in Figs 6.3 and 6.4. 
6.2.2 Reagents 
All ANS and acidic drug binding studies were carried out in 
"trizma" buffer (0.1M tris(hydroxymethyl)-aminomethane hydrochloride) at 
pH 7 .4. For part of this work DAPN was obtained from Molecular Probes, 
USA. All other reagents and samples including pretreatments are as shown 
in the previous chapters. 
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Figure 6.1 Flow injection arrangement for conventional single 
channel methods 
Figure 6.2 Flow injection arrangement for conventional merging 
zone methods 
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6.2.3 Binding Measurements 
Binding was monitored by the fluorescence enhancement effects 
produced when the ligand (DAPN or ANS) is bound to the protein. In the 
case of competitive binding, the displacement of the ligand by the 
competing drug caused fluorescence quenching. Fluorescence wavelengths 
of 346nm (excitation) and 525nm (emission) were used for DAPN-oc1AAGP 
systems while wavelengths of 370nm (excitation) 470nm (emission) were 
used for the ANS-albumin systems. All measurements were made at 
pH 7.4 and at room temperature (300°K). 
6.2.3.1 Conventional f.i.a measurements 
In a single channel mode, measurements were made by injecting 
various concentrations of DAPN into the reagent stream (oc1AAGP), or by 
injecting various concentrations of oc1AAGP into a DAPN stream. Both 
methods were used, the former being more suitable for binding data 
analysis. In competitive binding studies drug solutions were injected into a 
carrier stream of DAPN-oc1AAGP complex, or oc1AAGP with various 
concentrations of added drug were injected into a stream of DAPN 
solution. 
In the merging zone method the procedures were the same as in 
the single channel mode except that the sample and reagent were injected 
into separate carrier streams and were made to merge just before the 
reaction line. 
In conventional f.i.a experiments, measurement was recorded for 
every injection as a fluorescence signal in the form of a peak, the height of 
which was proportional to the concentration of the analyte reaching the 
detector. Three determinations were made for each sample. In 
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preliminary experiments the effect of dispersion on the binding 
measurements was studied by making changes in tube length or flow rates 
and the optimum dispersion was found to be 2.5. Dispersion was 
determined using lppm of quinine sulphate solution in 0.05M H2so 4 
<A-ex 350nm and Aem 450nm). 
6.2.3.2 Gradient f.i.a measurements 
In this method the binding titration used a concentration gradient 
generated in a mixing chamber following a single injection of the titrant. 
The method involved calibration of the mixing chamber, and the actual 
binding measurements. 
Calibration of mixing chamber 
The performance of the mixing chamber (either a well stirred 
mixing tank or a length of tubing) was studied using quinine sulphate 
solution (lppm) as follows: 
The mixing chamber was first equilibrated with the solvent 
(blank). The blank stream was then interchanged with the quinine sulphate 
stream by injection (Fig. 6.4) or with the four-way valve (Fig. 6.3). When the 
concentration of the flowing stream changed from C0 (solvent) to Cmax 
immediately prior to the mixing chamber. 
et = cmax (1 - exp(-kt)) (20) 
when et = concentration of quinine sulphate at time t at the 
mixing chamber exit. 
k = flow rate = u 
volume of mixing chamber V 
t = time of flow through the mixing chamber. 
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Since fluorescence (F) is proportional to the concentration of quinine 
sulphate 
F t = F max (1 - exp (-kt)) (21) 
= 
or 
kt. (22) 
Similarly when the concentration of quinine sulphate is changed from 
F t = F max exp(-kt) (23) 
therefore 
ln = kt (24) 
From the above equations the exponential rise or decay of 
concentration in the mixing chamber were checked. The value of k and 
hence the effective volume of the mixing chamber V were then calculated. 
The same relationships were used at all times to calculate concentrations 
of any analyte passed through the mixing chamber. A flow rate of 
2ml /min was found suitable for all the gradient f.i.a experiments. 
In practice a correction needs to be applied because the time 
measurements have an undefined origin. The equations thus become: 
ln Fmax = (25) 
and 
In Fmax ~ (26) 
respectively. 
tm = time measured. 
te = time error. 
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The time error is easily obtained as intercept from the plot, and the 
corresponding error in concentration can then be calculated. When k is 
small i.e. in a large mixing chamber, tm is large and te becomes negligible. 
The exponential behaviour of the mixing chamber (which is in fact 
due to the whole manifold between the point of sample introduction and 
detector) was also investigated in the presence of a merging stream shown 
in Figs 6.3 and 6.4. 
Binding measurements 
The system and flow rates used for all binding and calibration 
measurements were the same. Binding measurements were obtained using 
merging and single channel methods. 
In the merging method the stream of ligand (DAPN or ANS) from 
the mixing chamber was merged with the protein stream in a Y -junction 
(Figs 6.3 and 6.4). A solution of sample, of continuously varying 
concentration, was hence titrated with a continuous stream of a constant 
concentration of reagent. In competitive binding measurements the sample 
was the drug and the reagent was the protein-ligand complex. In these 
studies mixing of the reagent and sample took place between the 
Y-junction and the detector. A lOOcm length of tubing was found adequate 
for most of the systems studied. 
In the single channel method, the mixing chamber was first 
equilibrated with the reagent, which was then interchanged with the 
sample stream (or vice versa). In this method the concentrations of both 
sample and reagent vary simultaneously and the mixing of reagent and 
sample occur in the whole manifold including the mixing chamber. The 
single channel method using tubing was carried out by injecting a large 
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bolus of sample into the reagent stream. Two chambers are produced 
hence two peaks, one at the front of the injected sample and the other at 
the trailing end of the sample. The "mixing chamber" at the trailing end of 
the sample was chosen in this work; it offered conditions for more accurate 
time measurements. 
6.2.3.3 Static measurements 
For the purposes of comparison binding measurements were 
carried out in the same fluorimeter using a silica cell (lcm) at the same 
conditions and concentrations as in the f.i.a methods. 
6.3 Data Presentation and Analysis 
6.3.1 Static Method 
Analysis of data was carried out in exactly the same way as in 
section 4.2. 
6.3.2 Conventional f.i.a Method 
Equations used for the binding data were . exactly the same as 
those used for the static method except for the dispersion factor which has 
to be taken into account. 
6.3.3 Gradient f.i.a Method 
In this method the exponential behaviour of the mixing chamber 
given by equations (21) and (23) has to be used in the computation of the 
binding data as shown below. 
6.3.3.1 The merging method 
Single binding 
If the protein is in the merging stream 
eo 
B = C
max f2 
B • -' 
fT 
CLa"<1 - exp (-kt)) f 1 
fT 
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c~ax = total concentration of the protein stream before 
merging; 
CLax = total concentration of the ligand stream entering the 
mixing chamber; 
f1 = flow rate of the ligand stream; 
f 2 = flow rate of the protein stream; 
fT = · total flow rate after merging (f1 + f2); 
k = ¥ as in calibration; 
t = time; 
CJ3 and Cl, are as in the static method Cl, is the concentration of the 
ligand available for the binding which varies with the time. cj3 is the 
concentration of the potential binding sites after merging. 
A normal binding curve, enhancement versus c1o, can be obtained ~L.s by computing cl, from the exponential equation. Also whe'/(substituted 
into equation (18) .· 
1 
1 
. 1\ 
a 
f 1 Cmax (1 - exp (-kt)) rr L 
= 
and the equation can be represented as below; 
1 
y • ~ = X - C 
(27) 
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F t = fluorescence enhancement at time t; 
F max = fluorescence enhancement due to completely bound 
protein, cj3 
Competitive binding 
If protein-ligand complex is the merging stream 
CBL cmax 
f2 
= 
·r: BL T 
or eo Cmax f2 B = B . 1: ' T 
eo Cmax f2 L = L . r , T 
and f1 eo 
= 
cmax (1 - exp (-kt)) 
·r: D D T 
D stands for the competing drug. 
Equation (19) then becomes 
[ cg'"' (I - mq>(-ktll 
·1- ~-~J Ft c~ax . f2 max 1- -F- K T.f max = 
Ft 
cmax Ft Fmax L 
cmax Fmax B 
(28) 
of the form [Y = KX] 
6.3.3.2 Single channel method 
Single binding 
If the mixing chamber is first 
e(\}.1.\. \i. l:ira.ke.d A · with the protein before 
the ligand is passed through, 
eo B = 
therefore 
and 
cmax 
B 
R 
eo L 
= 
= 
exp(-kt) or Fmax = F~ax exp(-kt) 
F 
Fmax 
= po 
max 
C max (1 - exp (-kt)) L 
Ft 
exp (-kt) ' 
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F~ax = fluorescence enhancement due to total concentration 
of protein at time 0. 
Other symbols as above. · 
After substitution and simplification equation (18) becomes 
1 
(exp(-kt)) - F t 
po--
max 
of the form y 
Competitive binding 
1 = crax (1 - exp (-kt)) 
Ka Ft 
y-o-
max 
1 
~ = X - C 
Cmax - n p (29) 
If the chamber is saturated with the protein-ligand complex 
solution and then interchanged with a stream of drug solution, 
Cik = cmax BL exp (-kt) 
or eo B = 
cmax 
B exp (-kt), 
eo cmax exp (-kt) L = L 
and eo D = 
Cmax 
D (1 - exp (-kt). 
and R = Ft exp (-kt) po--
max 
therefore l' 1 Ft = 
F:;,ax exp(-kt) 
Equation (19) then becomes 
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1- Ft 
F ::.ax exp (-kt) 
= K. 
c~ax (1 - exp(-kt) ~ 
- 1-
c;rax exp(-kt) 
Ft ~ 
F ::.ax exp(-kt) 
(30) 
F t exp (-kt) 
~ 
max 
of the form Y = KX. 
cmax Ft 
1 
- F ::.ax exp (-kt) 
cmax 
B 
The binding parameters were all evaluated by plotting y against x in the 
single bindings, or Y versus X in the competitive bindings. 
6.4 Results and Discussions 
6.4.1 Conventional f.i.a 
Results were obtained directly in the form of peak heights which 
are reproducible to about 1% for the single channel method and 2% for the 
merging zone method. An average of fifty determinations per hour was 
possible, which is more than adequate for a complete binding titration. 
DAPN-oc1 AAGP binding curve is shown in Fig. 6.5. This is 
enhancement effects due to DAPN binding against the concentration of the 
DAPN. For the curve, the non-negligible fluorescence of the free DAPN 
had to be subtracted, which was obtained by the injection of DAPN into 
pure buffer stream. Competitive binding curves obtained are of two kinds. 
An example of the first kind is shown in Fig. 6.6, which is the plot of 
fluorescence enhancement produced when oc1AAGP plus various concen-
trations of the drug were injected into the DAPN stream, versus the 
concentration of the drug. In the second type, the fluorescence quenching, 
produced when various drug concentrations were injected into a stream of 
DAPN-oc1AAGP complex, was plotted against the concentration of the 
drug, Fig. 6. 7. Both types of binding are obtainable with the merging zone 
method as well, an example given in Fig. 6,8. 
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CONCENTRATION OF DAPN 
Figure 6.5 DAPN-oc1AAGP binding curve by conventional f.i.a, 
single channel method. Concentration of oc1AAGP, 0.88pM; 
Flow rate, 2.5mls/min; Reaction line, lOOcm, O.Smm i.d; 
Sample volume, 20pl. 
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CONCENTRATION OF PROPRANOLOL (mM) 
Figure 6.6 Displacement of DAPN from oc1AAGP by propranolol, 
by conventional f.i.a, single channel method.· DAPN stream, 
5.9pM; Injected oc1AAGP, 2.04pM; Flow rate, 2.5mls/min; 
Reaction line, lOOcm, 0.5mm i.d; Sample volume, 20pl. 
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CONCENTRATION OF IMIPRAMINE mM 
Figure 6.7 Displacement of DAPN from oc1AAGP by imipramine, 
by conventional f.i.a, single channel method. oc1 AAGP 
-DAPN stream, 2.02pM oc1AAGP + 7.50pM DAPN; Flow 
rate, 2.5mls/min; Reaction line, lOOcm, O.Smm i.d; Sample 
volume, 20jll; IF, fluorescence intensity. 
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CONCENTRATION OF PROPRANOLOL (mM) 
Figure 6.8 Displacement of DAPN from oc1AAGP by propranolol, 
by conventional f.i.a, merging zone method. Concentration 
of reagent, 2.07pM oc1AAGP + 8.91JM DAPN; Volume of 
sample and reagent injected, 351Jl each; Reaction line, 
160cm, 0.5mm i.d; Flow rate after merging, 5.0mls/min; IF, 
fluorescence intensity. 
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Examples of plots of equations (18) and (19) are given in Figs 
6.16, 6.22 to 6.24, as compared with other methods, and the binding 
parameters are presented in Table 6.1 and Tables 6.3-6.7. 
From preliminary experiments, dispersion changes produced 
changes in peak heights. The optimum dispersion for maximum peak 
height, hence sensitivity, was found to be 2.5 for the injected zone. 
However changes in dispersion from 1.8 to 4.0, produced either by changes 
in flow rate or length of tubing, caused no significant change in the 
calculated binding parameters, as shown in Table 6.2. 
Table 6.1 DAPN-oc1AAGP binding by conventional f.i.a, 
single channel method 
Concentration Number of Binding constant 
of oc1AAGP binding sites (Ka)M-1 (!I M) (n) 
2.81 1.06 2240000 
1.10 1.10 2700000 
0.88 0.99 2850000 
Table 6.2 The effect of dis2ersion on DAPN 
binding parameters 
Binding Number of 
Dispersion constanl binding sites (K
8
) M- (n) 
1.8 2510000 1.05 
2.5 2320000 1.07 
3.0 2480000 1.10 
4.0 2570000 1.03 
Concentration of oc1AAGP = 1.05!1M. 
Table 6.3 DAPN-a1AAGP binding by conventional f.i.a, 
merging zone method 
Concentration ·Number of Binding constant 
of a 1AAGP binding sites (Ka) (pM) (n) 
3.00 1.04 2100000 
1.20 1.06 2430000 
1.00 1.10 2900000 
Table 6.4 Propranolol binding displacements by conventional 
f.i.a, single channel method 
Concentration 
of a 1AAGP 
(pM) 
2.10 
1.05 
Propranolol binding constant 
49100 
51200 
Table 6.5 Propranolol binding displacement by conventional 
f.i.a, merging zone method 
Concentration 
of a 1AAGP 
(pM) 
2.07 
1.03 
Propranolol binding constant 
50000 
51700 
166 
M -1 
Table 6.6 
Concentration 
of oc1AAGP 
1.04 
2.02 
Table 6.7 
Concentration 
of oc1~AGP 
1.03 
2.07 
Binding displacement of other drugs by 
conventional f.i.a, single channel method 
Drug binding constant 
390000 
100000 
Drug 
Chlorpromazine 
Imipramine 
Binding displacement of other drugs by 
conventional f.i.a, merging zone method 
Drug binding constant 
440000 
130000 
Drug 
Chlorpromazine 
Imipramine 
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The results obtained by the conventional f.i.a method compare 
very well with those from the static method. The existence of one strong 
binding site, for the DAPN on oc:1AAGP, has been shown clearly with the 
binding affinity very much the same as in the static method. The presence 
of weaker binding sites is obvious on most of the graphs. Although the 
precision in the merging zone method is less than in the single channel 
method, both methods showed excellent agreement with the static 
methods, calculated and given in Tables 6.11 and 6.12. This demonstrates 
the suitability and applicability of conventional f.i.a with all its inherent 
advantages for the study of basic drug binding. 
_I 
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6.4.2 Gradient f.i.a 
6.4.2.1 Calibration of mixing chamber 
Exampl~s of calibration plots are shown in Figs 6.9 and 6.10. The 
calibration results which were calculated by least square fits are given in 
Table 6.8. The results show a very good performance of the mixing 
chambers which forms the basis of the binding titrations. The use of a 
merging stream did not cause any deviation from the expected behaviour of 
the mixing chambers. As shown in the graphs and results, the time error is 
smaller and the correlation coefficient is better for the large mixing 
chambers. It is obvious, however, that large volumes of solution are 
required to saturate a large mixing chamber. 
Table 6.8 Performance of mixing: chambers in the 
gradient f.i.a 
Effective Standard Working 
Type volume Correlation error of time 
(mls) coefficient estimation range (m Is) (secs) 
Mixing tank 6.99 0.9999 0.027 300 
6.99* 0.9999* 0.025* 
Mixing tank 0.396 0.9998 0.038 65 
0.396* 0.9998* 0.040* 
Tubing 0.260 0.9997 0.040 25 
0.260* 0.9997* 0.041* 
0.549 0.9997 0.061 80 
* Results with a merging stream 
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3 
T I ME (S) 
Figure 6.9 Calibration plot for gradient f.i.a. Volume of mixing 
Fm • 
chamber, 6.99mls; Ar = In F -F , F m is maximum 
m 
fluorescence intensity; F = fluorescence intensity at time t. 
6.4.2.2 Binding titrations 
All results of the binding titrations were directly generated as 
continuous plots of fluorescence intensity against time as shown in Figs 
6.11-6.14. In the merging method the binding curves generated, Figs 6.11 
and 6.14, are similar to those obtained in the usual static method. In the 
single channel method, however, the binding curves, Figs 6.12 and 6.13, 
have a peak maximum at the equivalence point (Q) of the titration. For 
both merging and single channel methods, there was a good repeatability of 
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Figure 6.10 Calibration plot for gradient f.i.a using tubing. 
Volume of mixing chamber, 260j.!l; Ar as in Fig. 6.9. 
the binding titrations with the maximum deviation in timing of about 0.2 of 
a second. 
A whole titration curve was generated within 5-10 minutes with 
the large mixing chambers, and within seconds with the small mixing 
chambers. Large mixing chambers provide longer titration time, hence 
accurate time measurements are easier. For small mixing chambers, the 
shorter time required obviates the need for careful time measurements and 
procedures in order to minimise the significance of the time error, te, as 
explained in the text, equations (25) and (26). Other advantages of using a 
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TIME (S) 
Figure 6.11 ANS-albumin binding curve by gradient f,i,a using 
tubing for dispersion, and a merging stream. Merging stream, 
0.87J1M albumin; Sample stream, ANS (initial concentration 
er) 8.34J1M; Volume of mixing chamber, 260J1l; IF -
fluorescence intensity. 
well stirred mixing chamber in f.i.a have been given in the literature134 
such as the elimination of possible effects of viscosity, specific gravity and 
temperature changes. 
Normal binding curves (plot· of fluorescence enhancement versus 
concentration) were obtained by computing the concentrations from the 
times, for example Fig. 6.15. The binding parameters were evaluated by 
plotting equations (27) to (30) and examples of the plots are given in Figs 
6.16-6.24 compared to static and conventional f.i.a methods. The binding 
parameters calculated are also given in Tables 6.9-6.12. 
2 
1 
T M E 
Figure 6.12 ANS-albumin binding curve by gradient f.i.a using a 
well stirred mixing tank, single channel mode. Reagent, 
l.OO!IM ANS; Sample, 0.23!1M albumin; IF, fluorescence 
intensity; Volume of mixing chamber, 0.396mls. 
Table 6.9 ANS-albumin binding, gradient f.i.a 
compared to static methods 
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Method Binding constant (M-1) Number of 
(Ka) 
binding sites 
(n) 
Static 2100000 0.93 
Mixing tank 
(6.99mls) 2300000 0.90 
plus merging 
Dispersion tubing 
(260!11) 2100000 0.90 
plus merging 
Mixing tank 
(6.99mls) 1800000 0.85 
single channel 
Dispersion tubing 
(549pl) 2000000 0.80 
single channel 
Concentration of albumin = 4.94pM. 
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T I M E (S) 
Figure 6.13 ANS-albumin binding curve by gradient f.i.a using 
tubing, single channel mode. 1.93J1M albumin was injected 
into a stream of 10.62J1M ANS. Volumes of mixing chambers, 
1.66)11 for the front and 549)11 for the rear of the sample 
plug; Ip, fluorescenee intensity. 
Table 6.10 Displacement bindings of acidie drugs, 
gradient f.i.a eompared with statie method 
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Drug binding constant (M -l) 
Method 
Statie 
Gradient f.i.a 
(Volume of 
mixing chamber 
= 260)11) 
Gradient f.i.a 
(Volume of 
mixing chamber 
= 6.99mls) 
Drug 
Flufenamic 
aeid 
Warfarin 
Flufenamic 
acid 
Warfarin 
Flufenamic 
acid 
1080000 
360000 
800000 
1000000* 
240000 
300000* 
1200000 
(alb] = 0.731JM; (ANS] = 4.721JM; "' Correeted for time error (t ) 
·~ 
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Figure 6.14 Displacement of ANS from albumin by flufenamic 
acid, gradient f.i.a using tubing for dispersion and a merging 
stream. Merging stream, 4.17pM ANS + 0. 73pM albumin; 
24.5pM flufenamic acid was injected <c£rl; Volume of mixing 
chamber, 260pl; IF, fluorescence intensity. 
Table 6.11 DAPN-<X1AAGP bil)ding, gradient f.i.a 
compared to static methods 
Method 
Static 
Gradient f.i.a 
(Volume of mixing 
chamber= 260pl) 
+merging 
Number of 
binding sites 
(n) 
1.10 
1.06 
Concentration or <X1AAGP = 1.04pM 
Binding constant (M - 1) 
2900000 
3000000 
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Figure 6.15 ANS-aJbumin binding curve by gradient f.i.a, single 
channel mode. Volume of mixing chamber, 6.99mls; 
Concentration axis computed from the time; Q, equivalence 
point; Ip,fluorescence intensity. 
Table 6.12 Displacement binding of basic drugs, gradient 
f.i.a compared to static methods 
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Method Drug 
Association constant or drug 
(M-1) 
Static 
Gradient f.i.a 
(Volume of mixing 
chamber= 260!11) 
plus merging 
Propranolol 
Chlorpromazine 
Imipramine 
Propranolol 
Chlorpromazime 
Imipramine 
Concentration of <X1AAGP 
Concentration of DAPN 
= 1.2511M 
= 7.50JJM 
54000 
420000 
110000 
57000 
400000 
120000 
y~-------------------------
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4 
0 
)( . 
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Figure 6.16 Plot of equation (29), DAPN-o::1AAGP binding. 
Concentration of o::1AAGP, 1.04JJM; ••• Static method; 
xxx - gradient f.i.a using tubing (260Jll) and a merging 
stream. ooo - Conventional f.i.a, single channel method; 
(Concentration of o:: 1AAGP, l.lOJJM); y and x as in text. 
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The results from the gradient f.i.a and the static methods showed 
very good agreement. Despite the possible problems associated with small 
' 
mixing chambers, just as good agreement is shown by all the DAPN 
systems, competitive and single bindings. The agreement is also good for 
ANS-albumin binding. For ANS and acidic drug competitive bindings, there 
32 
• 
24 
Figure 6.17 Scatchard plot, ANS-albumin binding. Concentration 
of albumin, 4.94pM; Static method; xxx - Gradient 
f.i.a using tubing, volume of mixing chamber (260pl) and 
merging method. 
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are obvious deviations in the gradient f.i.a competitive binding plots (Fig. 
6.20). Deviations are greater for smaller mixing chambers, and for the 
drug warfarin. The deviation may arise entirely due to the nature of the 
y 
• 
5 
0 ~o----~--~4~L--L----~ao----L----~,2~--x_J 
Figure 6.18 Plot of equation (29) ANS-albumin binding. Concen-
tration of albumin, 5.35).JM; ••• Static method; xxx -
Gradient f.i.a using a mixing tank (6.99mls), and a merging 
stream; y and x are as in text. 
178 
ANS-albumin binding inhibition by the acidic drugs; or partly due to the 
errors associated with the small mixing chamber; or due to kinetic effects. 
The mixing time allowed by the methods might not have been adequate for 
the acidic drug binding displacements. The same reasons could explain the 
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Figure 6.19 Plot of equation (29) ANS-albumin binding by gradient 
f.i.a using a mixing tank (6.99mls), single channel mode; 
Concentration of albumin, 4.94pM: y and x are as in text. 
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failure of weak basic drugs (phenyl propanolamine and diethylcarbamazine) 
to displace DAPN in the gradient f.i.a method, although displacement by 
the weak basic drugs was observed in the static method. 
In the single channel method, the binding curves clearly define the 
equivalence point of the titration from which the stoichiometry of the 
y 
8 
4 
30 X 
Figure 6.20 Flufenamic acid and ANS competitive binding to 
albumin by gradient f.i.a using tubing (260pl) and a merging 
stream (ANS + albumin). Concentration of albumin, 0. 73pM; 
Concentration of ANS, 4. 72pM; X and Y as in text, 
equation (30). 
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binding can easily be calculated. It also depicts the total number of 
binding sites including the weaker ones, which are not always distinct in 
the other methods, where the strong binding sites always dominated. For 
ANS-albumin binding, the stoichiometry was found to be 1:2.73, albumin to 
yr-------------------~ 
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• X. 
2 4 6 X 
Figure 6.21 Flufenamic acid and ANS competitive binding to 
albumin. Concentration of albumin, 0.73pM; Concentration 
of ANS, 4.72pM; .•. Static method; xxx - Gradient f.i.a 
using a mixing tank (6.99mls) and a merging stream (ANS + 
albumin). X and Y as in text, equation (30). 
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ANS ratio (Fig. 6.15). This method is not suitable for the DAPN system, 
due to the fluorescence of the free DAPN which complicates the binding 
curves and the calculations, but is nevertheless possible. 
On the whole the binding results obtained from all the f.i.a 
methods showed very good agreement with those from the static method, 
y 
200 30 X 
Figure 6.22 Propranolol and DAPN competitive binding. Concen-
tration of <X1AAGP, 1.2511M; Concentration of DAPN, 7.511M; 
••• Static method; xxx- Gradient f.i.a using tubing (260111) 
and a merging stream (DAPN + <XI AAGP); ooo - Convent-
ional f.i.a, single channel method (concentration of <X1AAGP, 
1.0511M); X and Y as in text, equation (30). 
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the f.i.a providing a more convenient, faster and economical method. In all 
the f.i.a methods, solution handling and volumetric errors have been 
reduced, compared to the static method. Gradient f.i.a excelled in 
. 01\. 0-m\>\>.'<l\. C>} 
providing greater speed. Continuous titration generate~ enormous), data. 
y,-------------------~ 
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Figure 6.23 Imipramine and DAPN competitive binding. Concen-
tration of (){1AAGP, 1.251JM; Concentration of DAPN, 7.51JM; 
••• Static method; xxx - Gradient f.i.a using tubing (260J1l) 
an·d a merging stream ((){1 AAGP + DAPN); ooo - Convent-
ional f.i.a, merging zone method (concentration of (){ 1AAGP, 
2.02].1M); X and Y as in text, equation (30). 
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The generation of a binding curve at once by a single injection eliminated 
most solution handlings and errors, and allowed easy calculation of data by 
interfacing to a microcomputer. 
y 
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Figure 6.24 
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Chlorpromazine and DAPN competitive binding. 
Concentration of cx1 AAGP, 1.25)JM; Concentration of DAPN, 
7.5pM; ••. Static method; xxx - Gradient f.i.a using tubing 
(260)JI} and a merging stream (DAPN + cx1 AAGP); ooo -
Conventional f.i.a, single channel method; X and Y as in text, 
equation (30). 
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Chapter 7 
CONCLUSION 
\ 
The luminescence of alpha-1-acid glycoprotein was found to be 
that of a typical protein, despite the high carbohydrate content of the 
oc1AAGP. The luminescence is predominantly that of tryptophan. When a 
drug molecule binds to oc1AAGP quenching of the protein fluorescence is 
possible, and was observed with chlorpromazine. Although binding 
measurements are possible from the quenching effects, protein fluor-
escence quenching is not suitable because of the nature of protein 
fluorescence. 
DAPN was found to be a good probe for oc1AAGP because: 
(1) The enhancement effect of about ten times observed when bound 
to oc1AAGP permits sensitive binding measurements; 
(2) There is a Stokes' shift of about 180nm which eliminates 
interference from scatter, and the fluorescence emission 
maximum at 525nm is far removed from major background 
interferences, particularly from serum samples; 
(3) DAPN is sufficiently soluble in buffer and in protein solutions; 
# 
(4) DAPN is stable in the free form and as a complex both under 
measurements conditions and on storage; 
(5) The binding of the DAPN to oc1 AAGP is specific at definite 
binding sites and the binding affinity is suitably high (approx. 3 x 
106M-1); 
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(6) The ease with which other serum protein interferents (albumin 
and lipoproteins) can be removed by a simple routine procedure 
which permits DAPN-oc1 AAGP binding analysis in serum samples. 
The competitive binding of DAPN'and basic drugs allows DAPN to 
be used successfully as a probe for. basic drug binding to oc1AAGP. It 
provides fast and sensitive methods; of studying drug binding displace-
ments, of estimating association constants of the basic drugs and of 
studying the nature of the drug binding site on oc1AAGP. The competition 
of DAPN with other binding species for a 1 AAGP binding can also be 
investigated and studied. The binding of basic drugs to other serum 
proteins (for example, albumin and ~-lipoproteins) can be studied by the 
use of the DAPN. 
Automation by flow injection analysis brought added advantages 
of convenience, speed and sample economy to the basic drug-protein 
binding study; the gradient f.i.a method providing a package for accurate 
and instant measurements of the binding curves and analysis of the binding 
parameters. 
With the appearance of DAPN as a fluorescent probe, 
developments in the field of basic drug binding is likely. The binding of 
DAPN hence basic drugs to other acidic glycoproteins in rare serum 
samples (for example, fetuin) remains to be studied. More work is also 
required to completely establish the nature of the oc1AAGP binding site. In 
this work, the roles of; sialic acid, disulphide bridge, secondary and tertiary 
structure; and the effect of pH on the DAPN-a:1 AAGP binding have been 
studied. The amino acid sequence of the binding site, the contributions 
of the amino acid groups that form the binding site and the role of the 
carbohydrate moieties other than the sialic acid is yet to be investigated 
187 
and studied. Information about the sequence of amino acids at the binding 
sites can be gained from the binding of DAPN to fragments of <X1AAGP 
molecule; parts of the <X1 AAGP molecule able to bind DAPN with the 
same, or slightly lower, affinity as the intact protein. Another method is 
the binding of DAPN to chemically modified amino acid residues of the 
protein. 
DAPN is sufficiently fluorescent in its unbound form, which 
reduces the sensitivity and convenience of the method. It is, therefore, 
obvious that a fluorescent probe which possesses the probe requirements of 
DAPN, but which is non-fluorescent in the unbound form will be preferred • 
• 
• 
- - - - - ---------------~~~--~---~------------~ 
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